

CITATION REPORT

List of articles citing

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

DOI: 10.1126/science.1203486
Science, 2011, 331, 1565-70.

Source: <https://exaly.com/paper-pdf/51240630/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2280	Calcium-induced contraction of the rhizoplast of a quadriflagellate green alga. <i>Science</i> , 1978 , 202, 975-7	33.3	161
2279	The immunobiology of cancer immunosurveillance and immunoediting. 2004 , 21, 137-48		2015
2278	Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. 2010 , 28, 35-42		283
2277	Noise-assisted interactions of tumor and immune cells. 2011 , 84, 021927		13
2276	Oncolytic viruses: a step into cancer immunotherapy. 2011 , 1		2
2275	Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. 2011 , 3, 1235-51		39
2274	Hiding the road signs that lead to tumor immunity. 2011 , 208, 1937-40		14
2273	Type I interferon is selectively required by dendritic cells for immune rejection of tumors. 2011 , 208, 1989-2003		676
2272	Cancer immunotherapy comes of age. 2011 , 480, 480-9		2374
2271	A methodological framework to enhance the clinical success of cancer immunotherapy. 2011 , 29, 867-70		51
2270	Early steps of follicular lymphoma pathogenesis. 2011 , 111, 1-46		75
2269	Human leukocyte antigen-G in cancer: are they clinically relevant?. 2011 , 311, 123-30		43
2268	The dynamic nature of autophagy in cancer. 2011 , 25, 1999-2010		440
2267	Cancer: Why tumours eat tryptophan. 2011 , 478, 192-4		108
2266	Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. 2011 , 71, 7433-41		124
2265	Long-lived inflammatory signaling in irradiated bone marrow is genome dependent. 2011 , 71, 6485-91		31
2264	The role of inflammation in the pathogenesis of lung cancer. 2011 , 15, 1127-37		87

2263	Prognostic and predictive impact of intra- and peritumoral immune infiltrates. 2011 , 71, 5601-5	297
2262	Cross-Talk of Breast Cancer Cells with the Immune System. 2011 ,	2
2261	Vaccines for colorectal cancer and renal cell carcinoma. 2011 , 17, 283-93	4
2260	Evaluation of current cancer immunotherapy: hemato-oncology. 2011 , 17, 309-24	14
2259	Roles of the immune system in skin cancer. 2011 , 165, 953-65	114
2258	Cancer immunotherapy comes of age. 2011 , 29, 4828-36	336
2257	Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. 2011 , 31, 1095-104	32
2256	Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance. 2011 , 137, 1525-33	31
2255	IFN- γ and IL-17 and TGF- β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. 2011 , 11, 33	66
2254	Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. 2011 , 23, H217-47	384
2253	Cancer immunotherapy: Progress and challenges in the clinical setting. 2011 , 41, 1510-5	23
2252	Molecular mechanisms of tumor angiogenesis. 2011 , 2, 1085-96	132
2251	The tumor microenvironment: part 1. 2011 , 3, 1367-84	18
2250	Plasmacytoid dendritic cells and cancer. 2011 , 90, 681-90	64
2249	Tumor stress inside out: cell-extrinsic effects of the unfolded protein response in tumor cells modulate the immunological landscape of the tumor microenvironment. 2011 , 187, 4403-9	64
2248	Defining the role of the immune system in cancer treatment: highlights from the Immunochemotherapy Conference. 2011 , 11, 841-3	1
2247	The two faces of interferon- β in cancer. 2011 , 17, 6118-24	397
2246	C-type Lectin Receptors for Tumor Eradication: Future Directions. 2011 , 3, 3169-88	7

2245	Tumor evasion from T cell surveillance. 2011 , 2011, 918471	105
2244	Synergistic effect of p53 on TSA-induced stanniocalcin 1 expression in human nasopharyngeal carcinoma cells, CNE2. 2012 , 48, 241-50	9
2243	Modulation of tumor tolerance in primary central nervous system malignancies. 2012 , 2012, 937253	14
2242	Cancer, Autoimmunity, and Psychosocial Stress. 2012 , 179-210	
2241	Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries?. 2012 , 23, 2720-2724	29
2240	Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. 2012 , 2012, 124187	31
2239	Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. 2012 , 2012, 818214	20
2238	Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. 2012 , 8, e1002926	57
2237	Soluble human leukocyte antigen-g and its insertion/deletion polymorphism in papillary thyroid carcinoma: novel potential biomarkers of disease?. 2012 , 97, 4080-6	28
2236	MYCN: from oncoprotein to tumor-associated antigen. 2012 , 2, 174	12
2235	The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. 2012 , 2012, 340296	109
2234	STAT1 and STAT3 in tumorigenesis: A matter of balance. 2012 , 1, 65-72	146
2233	Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. 2012 , 2012, 473712	64
2232	Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. 2012 , 2, 194	62
2231	The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytes. 2012 , 53, 598-604	14
2230	Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. 2012 , 287, 35484-35495	57
2229	The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. 2012 , 209, 1427-35	109
2228	Anesthesia in patients with cancer disorders. 2012 , 25, 376-84	50

2227	Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. 2012 , 20, 679-86	136
2226	Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. 2012 , 189, 3397-403	76
2225	Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. 2012 , 4, 127ra37	1562
2224	The interplay between inflammation and oxidative stress in carcinogenesis. 2012 , 12, 672-80	35
2223	Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. 2012 , 19, 1751-64	103
2222	Heat shock proteins (HSPs) based anti-cancer vaccines. 2012 , 12, 1183-97	43
2221	Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. 2012 , 1, 271-278	33
2220	Antigen shedding into the circulation contributes to tumor immune escape. 2012 , 1, 1620-1622	5
2219	Inefficient boosting of antitumor CD8(+) T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. 2012 , 1, 1507-1516	6
2218	TroVax(□) vaccine therapy for renal cell carcinoma. 2012 , 4, 27-42	11
2217	Gene-modified lymphocytes: from caution to promise for effective cancer immunotherapy. 2012 , 4, 241-4	
2216	A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. 2012 , 18, 4895-902	71
2215	[Hepatocellular carcinoma - from immunobiology to immunotherapy]. 2012 , 50, 47-56	9
2214	Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. 2012 , 1, 884-893	16
2213	Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future. 2012 , 1, 793-797	11
2212	Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. 2012 , 1, 908-916	92
2211	Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. 2012 , 1, 1027-1037	42
2210	Killing from within. 2012 , 1, 1598-1600	

2209	The early antitumor immune response is necessary for tumor growth: Re-visiting Prehn's hypothesis in the human melanoma system. 2012 , 1, 930-934	4
2208	Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?. 2012 , 1, 1617-1619	11
2207	Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. 2012 , 1, 1313-1322	10
2206	Radiotherapy supports protective tumor-specific immunity. 2012 , 1, 1610-1611	25
2205	Targeting NKG2D in tumor surveillance. 2012 , 16, 587-99	17
2204	The presence of high level soluble herpes virus entry mediator in sera of gastric cancer patients. 2012 , 44, 149-58	12
2203	Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides. 2012 , 18, 824-8	42
2202	Reply to: Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. 2012 , 18, 346-346	7
2201	Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. 2012 , 72, 3987-96	76
2200	Tissue stroma as a regulator of leukocyte recruitment in inflammation. 2012 , 91, 385-400	63
2199	Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors. 2012 , 13, 516-26	36
2198	Regulatory dendritic cells: there is more than just immune activation. 2012 , 3, 274	133
2197	Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs. 2012 , 1, 172-198	22
2196	Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. 2012 , 30, 1996-2004	167
2195	Lessons from cancer immunoediting in cutaneous melanoma. 2012 , 2012, 192719	17
2194	Eblockers: a novel class of antitumor agents. 2012 , 5, 391-401	20
2193	Improving TCR Gene Therapy for Treatment of Haematological Malignancies. 2012 , 2012, 404081	11
2192	Integrins and their extracellular matrix ligands in lymphangiogenesis and lymph node metastasis. 2012 , 2012, 853703	23

2191	Strategies for enhancing vaccine-induced CTL antitumor immune responses. 2012 , 2012, 605045	13
2190	Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity. 2012 , 2, 136	10
2189	Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. 2012 , 14, 584-95	96
2188	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. 2012 , 7, 267-72	11
2187	Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. 2012 , 40, 929-34	49
2186	Cytokine gene expression signature in ovarian clear cell carcinoma. 2012 , 41, 1094-100	36
2185	.	12
2184	Zinc and cancer: implications for LIV-1 in breast cancer. 2012 , 4, 648-75	73
2183	Pancreatic ductal adenocarcinoma: a review of immunologic aspects. 2012 , 60, 643-63	41
2182	Emerging evidence of anti-tumor immune control in the central nervous system. 2012 , 1, 1648-1649	3
2181	Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. 2012 , 119, 2176-7	35
2180	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. 2012 , 119, 3097-104	58
2179	CEBPE activation in PML-RARA cells by arsenic. 2012 , 119, 2177-9	8
2178	Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway. 2012 , 11, 3997-4008	30
2177	Immunogenic cell death and DAMPs in cancer therapy. 2012 , 12, 860-75	1165
2176	The sweet side of tumor immunotherapy. 2012 , 4, 719-34	15
2175	MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. 2012 , 72, 5463-72	99
2174	Future directions in cancer prevention. 2012 , 12, 835-48	164

2173	The pros and cons of chemokines in tumor immunology. 2012 , 33, 496-504	80
2172	Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. 2012 , 14, R21	24
2171	Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma. 2012 , 19, 822-7	6
2170	Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice. 2012 , 56, 1924-33	41
2169	Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. 2012 , 61, 1849-56	93
2168	Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. 2012 , 61, 1965-75	89
2167	The roles of mast cells in anticancer immunity. 2012 , 61, 1511-20	56
2166	Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). 2012 , 61, 2283-94	22
2165	Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. 2012 , 22, 494-505	85
2164	Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. 2012 , 2, 628-39	152
2163	The adaptive immune response to colorectal cancer: from the laboratory to clinical practice. 2012 , 38, 889-96	12
2162	Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach. 2012 , 43, 132-145	7
2161	Revealing the dynamic modularity of composite biological networks in breast cancer treatment. 2012 , 2012, 5432-6	1
2160	Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. 2012 , 189, 767-76	23
2159	Melanoma brain metastasis: overview of current management and emerging targeted therapies. 2012 , 12, 1207-15	57
2158	Immunotherapy earns its spot in the ranks of cancer therapy. 2012 , 209, 201-9	108
2157	Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. 2012 , 209, 495-506	220
2156	The antigen specific composition of melanoma tumor infiltrating lymphocytes?. 2012 , 1, 935-936	5

2155	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. 2012 , 11, 865-70	31
2154	Combination immunotherapy approaches. 2012 , 23 Suppl 8, viii41-6	103
2153	The secret ally: immunostimulation by anticancer drugs. 2012 , 11, 215-33	494
2152	Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. 2012 , 8, 1309-13	21
2151	Cancer. Immune surveillance from chromosomal chaos?. <i>Science</i> , 2012 , 337, 1616-7	33-3 4
2150	Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). 2012 , 26, 991-1000	34
2149	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. 2012 , 490, 412-6	397
2148	Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. 2012 , 41, 765-97	69
2147	Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response. 2012 , 13, 322-30	15
2146	CD73: a potent suppressor of antitumor immune responses. 2012 , 33, 231-7	253
2145	Liberating tumor immunity. 2012 , 24, 204-6	1
2144	Ras oncoproteins transfer from melanoma cells to T cells and modulate their effector functions. 2012 , 189, 4361-70	6
2143	Cancer immunoediting by the innate immune system in the absence of adaptive immunity. 2012 , 209, 1869-82	221
2142	Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. 2012 , 491, 254-8	873
2141	From China to Glasgow. 2012 , 42, i-ii	
2140	Interferon- β -induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. 2012 , 10, 41	79
2139	Toward integrative cancer immunotherapy: targeting the tumor microenvironment. 2012 , 10, 70	36
2138	PV1 down-regulation via shRNA inhibits the growth of pancreatic adenocarcinoma xenografts. 2012 , 16, 2690-700	10

2137	Anti-tumor immunity: myeloid leukocytes control the immune landscape. 2012 , 278, 21-6	18
2136	Trial watch: Dendritic cell-based interventions for cancer therapy. 2012 , 1, 1111-1134	134
2135	Increased risk of breast cancer associated with CC genotype of Has-miR-146a Rs2910164 polymorphism in Europeans. 2012 , 7, e31615	61
2134	Vitamin D and cancer: a review of molecular mechanisms. 2012 , 441, 61-76	245
2133	Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors. 2012 , 114, 217-43	27
2132	Increasing the efficacy of tumor cell vaccines by enhancing cross priming. 2012 , 325, 155-64	37
2131	Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. 2012 , 76, 118-22	16
2130	Recombinant viral vaccines for cancer. 2012 , 18, 564-74	28
2129	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. 2012 , 1, 1323-1343	173
2128	Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. 2012 , 114, 151-76	23
2127	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. 2012 , 18, 1224-31	322
2126	Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. 2012 , 23 Suppl 8, viii6-9	344
2125	Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential. 2012 , 9, 301-13	32
2124	Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. 2012 , 90, 869-71	3
2123	The immune contexture in human tumours: impact on clinical outcome. 2012 , 12, 298-306	2819
2122	Adenovirus-mediated delivery of interferon- γ gene inhibits the growth of nasopharyngeal carcinoma. 2012 , 10, 256	17
2121	Pathway-based evaluation in early onset colorectal cancer suggests focal adhesion and immunosuppression along with epithelial-mesenchymal transition. 2012 , 7, e31685	26
2120	Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. 2012 , 7, e32639	31

2119	Mechanical disruption of tumors by iron particles and magnetic field application results in increased anti-tumor immune responses. 2012 , 7, e48049	23
2118	Macrophage plasticity and polarization: in vivo veritas. 2012 , 122, 787-95	3579
2117	Regulatory T cells in inflammatory bowel diseases and colorectal cancer. 2012 , 18, 5688-94	27
2116	Effects of Diet-Derived Molecules on the Tumor Microenvironment. 2012 , 1, 206-214	4
2115	Cancer as an immune-mediated disease. 2012 , 1, 1-6	22
2114	Regulation of Tumor Angiogenesis by the Immune System. 2012 , 1, 88-97	2
2113	Reporter gene imaging of immune responses to cancer: progress and challenges. 2012 , 2, 355-62	15
2112	Does absolute neutrophil count predict high tumor grade in African-American men with prostate cancer?. 2012 , 72, 386-91	9
2111	T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. 2012 , 72, 1239-47	16
2110	The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells. 2012 , 13, 412-22	33
2109	Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. 2012 , 72, 1717-27	62
2108	Stromal estrogen receptor- β promotes tumor growth by normalizing an increased angiogenesis. 2012 , 72, 3010-9	75
2107	Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs. 2012 , 205 Suppl 2, S335-9	16
2106	Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. 2012 , 13, 832-42	488
2105	Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. 2012 , 14, 405-15	171
2104	The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. 2012 , 227, 367-79	33
2103	HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer. 2012 , 131, 150-7	28
2102	B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF- β perforin). 2012 , 131, 1499-508	23

2101	Cancer and inflammation: an old intuition with rapidly evolving new concepts. 2012 , 30, 677-706	361
2100	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. 2012 , 482, 400-4	849
2099	Immune surveillance of senescent cells--biological significance in cancer- and non-cancer pathologies. 2012 , 33, 1123-6	161
2098	Cellular constituents of immune escape within the tumor microenvironment. 2012 , 72, 3125-30	248
2097	Antibody-based immunotherapy of cancer. 2012 , 148, 1081-4	186
2096	Role of myeloid-derived suppressor cells in tumor immunotherapy. 2012 , 4, 43-57	27
2095	3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro. 2012 , 1, 590-9	67
2094	Adoptive immunotherapy for cancer: harnessing the T cell response. 2012 , 12, 269-81	1192
2093	Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. 2012 , 30, 1087-94	22
2092	Natural killer cell immune escape in acute myeloid leukemia. 2012 , 26, 2019-26	109
2091	Cancer immunotherapy: a paradigm shift for prostate cancer treatment. 2012 , 9, 376-85	25
2090	The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. 2012 , 3, 441-9	5
2089	Medulloblasoma: challenges for effective immunotherapy. 2012 , 108, 1-10	20
2088	Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. 2012 , 7, 55-68	33
2087	Fighting against cancer by integrative medicine. 2012 , 18, 323-4	5
2086	Investigation of NK cell function and their modulation in different malignancies. 2012 , 52, 139-56	51
2085	An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. 2012 , 460, 455-65	70
2084	Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. 2012 , 167, 188-94	21

2083	Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. 2012 , 167, 195-205	288
2082	Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. 2012 , 167, 216-25	18
2081	Experimental mouse tumour models: what can be learnt about human cancer immunology?. 2011 , 12, 61-6	85
2080	Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. 2012 , 21, 822-35	648
2079	Silencing the killers: paracrine immune suppression in pancreatic cancer. 2012 , 21, 715-6	11
2078	Origin and plasticity of MHC I-associated self peptides. 2012 , 11, 627-35	40
2077	Monoclonal antibodies for the treatment of cancer. 2012 , 22, 3-13	122
2076	Host-tumor interactions in nasopharyngeal carcinomas. 2012 , 22, 127-36	65
2075	Evolution and roles of stanniocalcin. 2012 , 349, 272-80	142
2074	Radiochemotherapy induces a favourable tumour infiltrating inflammatory cell profile in head and neck cancer. 2012 , 48, 594-601	39
2073	Review: insights gained from modelling high-grade glioma in the mouse. 2012 , 38, 254-70	15
2072	Langerhans cells and T cells sense cell dysplasia in oral leukoplakias and oral squamous cell carcinomas--evidence for immunosurveillance. 2012 , 76, 39-48	32
2071	Targeting HLA class I expression to increase tumor immunogenicity. 2012 , 79, 147-54	40
2070	The clinical implications of antitumor immunity in head and neck cancer. 2012 , 122, 144-57	45
2069	[Prostate carcinoma: vaccination as a new option for treatment]. 2012 , 51, 44-9	
2068	Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer. 2012 , 61, 335-42	8
2067	Dendritic cells and their role in tumor immunosurveillance. 2013 , 19, 98-111	35
2066	Site-specific cancer deaths in cancer of unknown primary diagnosed with lymph node metastasis may reveal hidden primaries. 2013 , 132, 944-50	21

2065	Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. 2013 , 11, 147	44
2064	Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. 2013 , 11, 70	23
2063	FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. 2013 , 32, 39	27
2062	Targeting the immune system for management of NSCLC: the revival?. 2013 , 2, 22-39	1
2061	Therapeutic cancer vaccines: past, present, and future. 2013 , 119, 421-75	361
2060	Can an engineer fix an immune system?--Rethinking theoretical biology. 2013 , 61, 223-58	1
2059	The immune microenvironment of human tumors: general significance and clinical impact. 2013 , 6, 117-22	93
2058	Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. 2013 , 62, 919-29	68
2057	Nivolumab plus ipilimumab in advanced melanoma. 2013 , 369, 122-33	3118
2056	Immunosurveillance as a regulator of tissue homeostasis. 2013 , 34, 471-81	41
2055	Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting. 2013 , 1,	4
2054	Innate immune reactions in locally limited tonsillar cancer. 2013 , 270, 2751-8	1
2053	The clinical implication of tumoral Gal-1 expression in laryngeal squamous cell carcinomas. 2013 , 15, 608-18	1
2052	High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. 2013 , 352, 351-9	50
2051	Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery?. 2013 , 27, 731-41	36
2050	Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies. 2013 , 15, 797-807	22
2049	Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. 2013 , 1, 10	215
2048	[Immunotherapy of head and neck cancer. Current developments]. 2013 , 61, 559-72	2

2047	Historical Perspectives and Current Trends in Cancer Immunotherapy. 2013 , 3-15	3
2046	Stem Cells and Cancer Stem Cells, Volume 10. 2013 ,	
2045	Modulation of antitumour immune responses by intratumoural Stat1 expression. 2013 , 91, 556-67	9
2044	Autophagy and cellular immune responses. 2013 , 39, 211-27	296
2043	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. 2013 , 62, 1475-84	26
2042	Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. 2013 , 62, 629-37	40
2041	Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. 2013 , 62, 471-9	121
2040	Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. 2013 , 62, 553-61	67
2039	Protumor and antitumor functions of neutrophil granulocytes. 2013 , 35, 163-76	103
2038	Plasma Medicine. 2013 , 359-413	3
2037	Immunotherapy at large: the road to personalized cancer vaccines. 2013 , 19, 1098-100	41
2036	Targeting tumors with nonreplicating <i>Toxoplasma gondii</i> uracil auxotroph vaccines. 2013 , 29, 431-7	26
2035	Targeting the immune system in the treatment of non-small-cell lung cancer. 2013 , 14, 580-94	11
2034	MyD88 and its divergent toll in carcinogenesis. 2013 , 34, 379-89	64
2033	Breast cancer management. 2013 , 67, 685-6	2
2032	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. 2013 , 25, 182-90	39
2031	Understanding clinical strategies that may impact tumour growth and metastatic spread at the time of cancer surgery. 2013 , 27, 427-39	24
2030	Inflammatory networks and immune surveillance of pancreatic carcinoma. 2013 , 25, 200-5	134

2029	Complement inhibition in cancer therapy. 2013 , 25, 54-64	95
2028	A balance of interleukin-12 and -23 in cancer. 2013 , 34, 548-55	85
2027	Cancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy. 2013 , 1284, 80-6	14
2026	Avirulent <i>Toxoplasma gondii</i> generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. 2013 , 73, 3842-51	56
2025	Mast cells: potential positive and negative roles in tumor biology. 2013 , 1, 269-79	113
2024	Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. 2013 , 145, 1121-32	310
2023	Interleukin-1 β 2013 , 25, 430-8	116
2022	Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. 2013 , 39, 611-21	294
2021	IDO Pathway. 2013 , 583-596	
2020	Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. 2013 , 39, 782-95	1595
2019	Immunologically augmented cancer treatment using modern radiotherapy. 2013 , 19, 565-82	73
2018	The Association Between Inflammation and Colorectal Cancer. 2013 , 67-105	1
2017	Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. 2013 , 5, 185ra63	72
2016	Immunology. Making macrophages eat cancer. <i>Science</i> , 2013 , 341, 41-2	33.3 27
2015	Microenvironmental regulation of tumor progression and metastasis. 2013 , 19, 1423-37	3959
2014	Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment. 2013 , 3, 1330-2	19
2013	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. 2013 , 31, 860-7	1023
2012	Poker face no more: cancer recurrence reveals its hand. 2013 , 19, 1569-70	3

2011	Tumor-associated immune parameters for personalized patient care. 2013 , 5, 214fs42	4
2010	Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. 2013 , 191, 4121-9	70
2009	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. 2013 , 19, 5300-9	485
2008	Perspective: Flicking with flow: Can microfluidics revolutionize the cancer research?. 2013 , 7, 11811	16
2007	Cancer immunotherapy: are we there yet?. 2013 , 2, 33	20
2006	The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities. 2013 , 57, 52-69	32
2005	Killing machines: three pore-forming proteins of the immune system. 2013 , 57, 268-78	41
2004	Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence". 2013 , 32, 403-21	33
2003	Autoimmunity vs. cancer: predator vs. alien?. 2013 , 46, 287-93	6
2002	Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. 2013 , 1284, 52-6	16
2001	Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy. 2013 , 1284, 57-61	5
2000	Hypothermic microenvironment plays a key role in tumor immune subversion. 2013 , 17, 245-53	17
1999	Immunotherapy at large: Balancing tumor immunity and inflammatory pathology. 2013 , 19, 1100-1	24
1998	Lung cancer: potential targets for immunotherapy. 2013 , 1, 551-63	55
1997	Systems Biology of Tumor Dormancy. 2013 ,	6
1996	Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. 2013 , 734, 91-107	26
1995	Detailed analysis of inflammatory cell infiltration in colorectal cancer. 2013 , 109, 1839-47	98
1994	The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. 2013 , 39, 11-26	554

1993	Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. 2013 , 39, 74-88	609
1992	Cancer Immunoediting. 2013 , 85-99	3
1991	Comprehensive Immunomonitoring to Guide the Development of Immunotherapeutic Products for Cancer. 2013 , 241-258	1
1990	Epigenetic Approaches: Emerging Role of Histone Deacetylase Inhibitors in Cancer Immunotherapy. 2013 , 353-372	1
1989	Optimal management of metastatic melanoma: current strategies and future directions. 2013 , 14, 179-94	65
1988	T-cell tolerance in cancer. 2013 , 5, 513-531	33
1987	GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. 2013 , 1, 320-31	114
1986	HLA ligandome tumor antigen discovery for personalized vaccine approach. 2013 , 12, 1211-7	72
1985	Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. 2013 , 122, 1105-13	115
1984	High molecular weight stress proteins: Identification, cloning and utilisation in cancer immunotherapy. 2013 , 29, 364-75	29
1983	Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?. 2013 , 9, 145-65	71
1982	Cutaneous tumors cease CXCL9/Mig production as a result of IFN- γ -mediated immunoediting. 2013 , 190, 832-41	19
1981	Memory T cells are uniquely resistant to melanoma-induced suppression. 2013 , 62, 149-59	6
1980	Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. 2013 , 137, 407-16	22
1979	The impact of minor histocompatibility antigens in allogeneic stem cell transplantation. 2013 , 39-58	
1978	Enforcement of reproductive synchrony via policing in a clonal ant. 2013 , 23, 328-32	40
1977	Phenotypic characterisation of immune cell infiltrates in testicular germ cell neoplasia. 2013 , 100, 135-45	27
1976	Strategies to reverse melanoma-induced T-cell dysfunction. 2013 , 31, 251-6	6

1975	Tumor-associated macrophages in thoracic malignancies. 2013 , 80, 256-62	47
1974	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. 2013 , 14, 1765-77	31
1973	Cancer immunotherapy: accomplishments to date and future promise. 2013 , 4, 1307-20	70
1972	Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. 2013 , 29, 464-73	25
1971	Zn- and Mg- containing tricalcium phosphates-based adjuvants for cancer immunotherapy. 2013 , 3, 2203	18
1970	Noncanonical roles of the immune system in eliciting oncogene addiction. 2013 , 25, 246-58	10
1969	Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. 2013 , 31, 639-46	26
1968	Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly. 2013 , 74, 640-7	4
1967	Time trends in survival from cancer of unknown primary: small steps forward. 2013 , 49, 2403-10	28
1966	The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. 2013 , 15, 133-42	148
1965	Translational research in melanoma. 2013 , 22, 785-804	
1964	Energy management - a critical role in cancer induction?. 2013 , 88, 198-217	12
1963	T-helper-1-cell cytokines drive cancer into senescence. 2013 , 494, 361-5	457
1962	Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. 2013 , 19, 2598-604	43
1961	Combining radiotherapy and cancer immunotherapy: a paradigm shift. 2013 , 105, 256-65	685
1960	Anti-tumour strategies aiming to target tumour-associated macrophages. 2013 , 138, 93-104	185
1959	Suppression, subversion and escape: the role of regulatory T cells in cancer progression. 2013 , 171, 36-45	147
1958	The cancer biology of whole-chromosome instability. 2013 , 32, 4727-36	90

1957	Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. 2013 , 14, 293-304	82
1956	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. 2013 , 144, 829-40	317
1955	Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon- γ . 2013 , 210, 605-21	58
1954	Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. 2013 , 445, 171-80	60
1953	Interaction of tumor cells with the immune system: implications for dendritic cell therapy and cancer progression. 2013 , 18, 35-42	6
1952	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. 2013 , 13, 365-76	191
1951	Modulating T regulatory cells in cancer: how close are we?. 2013 , 91, 340-9	31
1950	Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. 2013 , 38, 729-41	439
1949	Therapeutic gene modified cell based cancer vaccines. 2013 , 525, 200-7	39
1948	Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathways. 2012 , 3, 323	47
1947	Myeloid derived suppressor cells: Targets for therapy. 2013 , 2, e24117	55
1946	Physical Activity in Pediatric Cancer patients with solid tumors (PAPEC): trial rationale and design. 2013 , 36, 106-15	15
1945	Interferon- β : special immunomodulatory agents and potential therapeutic targets. 2013 , 5, 209-18	11
1944	Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. 2013 , 162, 313-25	76
1943	Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. 2013 , 25, 192-9	60
1942	Oral administration of soluble β glucans extracted from <i>Grifola frondosa</i> induces systemic antitumor immune response and decreases immunosuppression in tumor-bearing mice. 2013 , 133, 108-19	64
1941	Autophagy: shaping the tumor microenvironment and therapeutic response. 2013 , 19, 428-46	200
1940	Chapter 1: Targeted Drug Delivery in Oncology: Current Paradigm and Challenges. 2013 , 1-19	1

1939	Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. 2013 , 62, 1439-51	155
1938	Strategies for optimizing the response of cancer and normal tissues to radiation. 2013 , 12, 526-42	255
1937	The Tumor Immunoenvironment. 2013 ,	3
1936	Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. 2013 , 49, 2233-42	319
1935	Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia. 2013 , 61, 1178-90	75
1934	Generation of Antigen-Specific T Lymphocytes from Induced Pluripotent Stem Cells for Adoptive Immunotherapy. 2013 , 105-121	
1933	Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines. 2013 , 8, 7-14	45
1932	Tumor-derived microvesicles: the metastasomes. 2013 , 80, 75-82	19
1931	Innate immune cells in inflammation and cancer. 2013 , 1, 77-84	83
1930	Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. 2013 , 191, 3955-67	40
1929	T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. 2013 , 26, 441-56	11
1928	Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. 2013 , 110, 20176-81	198
1927	Methods for analysis of the immune system in mouse cancer models. 2013 , 2013, 901-3	2
1926	The functional impairment of HCC-infiltrating Γ T cells, partially mediated by regulatory T cells in a TGF β and IL-10-dependent manner. 2013 , 58, 977-83	68
1925	Janus kinase inhibitors in autoimmune diseases. 2013 , 72 Suppl 2, ii111-5	255
1924	Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. 2013 , 133, 120-9	72
1923	Blocking mtDNA replication upregulates the expression of stemness-related genes in prostate cancer cell lines. 2013 , 37, 258-66	4
1922	On the binding affinity of macromolecular interactions: daring to ask why proteins interact. 2013 , 10, 20120835	251

1921	Delphinidin is a novel inhibitor of lymphangiogenesis but promotes mammary tumor growth and metastasis formation in syngeneic experimental rats. 2013 , 34, 2804-13	10
1920	Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. 2013 , 132, 1971-6	59
1919	CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. 2013 , 132, E26-36	68
1918	Koch Institute Symposium on Cancer Immunology and Immunotherapy. 2013 , 1, 217-222	0
1917	Changing T-cell enigma: cancer killing or cancer control?. 2013 , 12, 3146-53	11
1916	Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. 2013 , 73, 1107-17	182
1915	Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. 2013 , 73, 3566-77	88
1914	Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma. 2013 , 1, 288-95	6
1913	[Perspectives on immunotherapy for hepatocellular carcinoma]. 2013 , 138, 740-4	2
1912	Immunotherapeutic strategies to target prognostic and predictive markers of cancer. 2013 , 7, 23-35	7
1911	[Immune-checkpoints: the new anti-cancer immunotherapies]. 2013 , 100, 601-10	7
1910	Second cancers early post allogeneic transplant: the case of 'unrestrained' malignancy?. 2013 , 48, 872-4	
1909	Porphyromonas gingivalis: keeping the pathos out of the biont. 2013 , 5,	45
1908	Dendritic cell-based immunotherapy for myeloid leukemias. 2013 , 4, 496	28
1907	Adoptive cell therapies for glioblastoma. 2013 , 3, 275	38
1906	Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. 2013 , 3, 63	66
1905	Improvement of cancer immunotherapy by combining molecular targeted therapy. 2013 , 3, 136	19
1904	Macrophage-tumor cell interactions regulate the function of nitric oxide. 2013 , 4, 144	58

1903	Immune infiltrates as predictive markers of survival in pancreatic cancer patients. 2013 , 4, 210	67
1902	Chromatin targeting drugs in cancer and immunity. 2013 , 27, 1731-8	22
1901	Carcinoma-associated fibroblasts are a promising therapeutic target. 2013 , 5, 149-69	110
1900	Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. 2013 , 2, e26137	21
1899	Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. 2013 , 19, 2775-86	96
1898	Characteristics of tertiary lymphoid structures in primary cancers. 2013 , 2, e26836	86
1897	Metastatic mechanisms in follicular cell-derived thyroid cancer. 2013 , 20, R307-19	32
1896	Current status of immunotherapy for the treatment of biliary tract cancer. 2013 , 9, 1069-72	13
1895	Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. 2013 , 36, 477-89	174
1894	Immunotherapeutics for breast cancer. 2013 , 25, 602-8	23
1893	Interactions between the tumor suppressor p53 and immune responses. 2013 , 25, 85-92	78
1892	Radiation-induced tumor dormancy reflects an equilibrium between the proliferation and T lymphocyte-mediated death of malignant cells. 2013 , 2, e25668	11
1891	Chronic mechanistic target of rapamycin inhibition: preventing cancer to delay aging, or vice versa?. 2013 , 38, 1-16	8
1890	The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone. 2013 , 2, e22339	12
1889	Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. 2013 , 2, e24743	18
1888	Predicting the efficacy of cancer vaccines by evaluating T-cell responses. 2013 , 2, e22616	5
1887	Tumor immunology: multidisciplinary science driving basic and clinical advances. 2013 , 1, 16-23	5
1886	A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. 2013 , 73, 2093-103	31

1885	Toll-like receptor 4 engagement drives differentiation of human and murine dendritic cells from a pro- into an anti-inflammatory mode. 2013 , 8, e54879	21
1884	What lies within: novel strategies in immunotherapy for non-small cell lung cancer. 2013 , 18, 1203-13	30
1883	Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. 2013 , 210, 2435-66	197
1882	Expression of leukotriene B ₄ receptor-1 on CD8 ⁺ T cells is required for their migration into tumors to elicit effective antitumor immunity. 2013 , 191, 3462-70	32
1881	GBP-1 acts as a tumor suppressor in colorectal cancer cells. 2013 , 34, 153-62	63
1880	Molecular insights for optimizing T cell receptor specificity against cancer. 2013 , 4, 154	27
1879	Biomarkers in precision therapy in colorectal cancer. 2013 , 1, 166-83	69
1878	Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. 2013 , 190, 5874-81	122
1877	Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. 2013 , 1, 245-55	52
1876	Current world literature. 2013 , 25, 99-104	
1875	Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM-CSF/CAIX in immunocompetent mouse models. 2013 , 36, 102-11	23
1874	Unique Versus Redundant Functions of IL-1 β and IL-1 α in the Tumor Microenvironment. 2013 , 4, 177	78
1873	Immunosuppressive microenvironment in neuroblastoma. 2013 , 3, 167	49
1872	Immune modulation and stereotactic radiation: improving local and abscopal responses. 2013 , 2013, 658126	56
1871	Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. 2013 , 4, 221	31
1870	Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients. 2013 , 28, 1555-64	21
1869	Myeloid TGF- β responsiveness promotes metastases. 2013 , 3, 846-8	4
1868	Non-classical MHC Class I molecules regulating natural killer cell function. 2013 , 2, e23336	3

1867	Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies. 2013 , 2, e24841	19
1866	Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. 2013 , 19, 4843-53	48
1865	Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. 2013 , 32, 4214-21	48
1864	The nuclear factor- κ B pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor- κ B inhibitors in cancer therapy. 2013 , 139, 265-74	4
1863	Bifurcations in Delay Differential Equations and Applications to Tumor and Immune System Interaction Models. 2013 , 12, 1847-1888	36
1862	Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. 2013 , 138, 280-92	16
1861	Dietary supplementation of Ashwagandha (<i>Withania somnifera</i> , Dunal) enhances NK cell function in ovarian tumors in the laying hen model of spontaneous ovarian cancer. 2013 , 70, 538-50	15
1860	Combat or surveillance? Evaluation of the heterogeneous inflammatory breast cancer microenvironment. 2013 , 229, 569-78	20
1859	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. 2013 , 133, 2895-902	31
1858	Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. 2013 , 190, 1882-9	11
1857	Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches. 2013 , 133, 2145-56	22
1856	Mesoporous silica-calcium phosphate-tuberculin purified protein derivative composites as an effective adjuvant for cancer immunotherapy. 2013 , 2, 863-71	29
1855	Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. 2013 , 73, 2381-8	115
1854	Regulatory T cells, leptin and angiogenesis. 2014 , 99, 155-69	20
1853	REST negatively and ISGF3 positively regulate the human STAT1 gene in melanoma. 2013 , 12, 1288-98	7
1852	Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis. 2013 , 3, 2845	19
1851	Trial watch: Dendritic cell-based interventions for cancer therapy. 2013 , 2, e25771	87
1850	Dysfunctional reproductive physiology, and not reproductive activation, triggers policing in experimental colonies of the clonal ant <i>Cerapachys biroi</i> . 2013 , 6, e24954	

1849	The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. 2013 , 98, 953-63	148
1848	Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. 2013 , 2, e23562	110
1847	Trial Watch: Immunostimulatory cytokines. 2013 , 2, e24850	44
1846	Thwarting galectin-induced immunosuppression in breast cancer. 2013 , 2, e24077	5
1845	Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. 2013 , 109, 1031-9	35
1844	Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages. 2013 , 91, 451-60	16
1843	Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. 2013 , 91, 105-14	39
1842	Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. 2013 , 110, 14711-6	244
1841	Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. 2013 , 19, 5626-35	293
1840	The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. 2013 , 15, 1479-90	49
1839	Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model. 2013 , 190, 6651-61	22
1838	STAT3 activation: A key factor in tumor immunoescape. 2013 , 2, e23010	113
1837	Conociendo y comprendiendo la célula cancerosa: Fisiopatología del cáncer. 2013 , 24, 553-562	1
1836	A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. 2013 , 122, 243-52	86
1835	The role of B7 family molecules in hematologic malignancy. 2013 , 121, 734-44	132
1834	[At the crossroads of cancer]. 2013 , 100, 569-74	3
1833	Can mouse models of cancer reliably improve clinical trial outcome?. 2013 , 3, 119-130	1
1832	The role of natural killer cells in pulmonary immunosurveillance. 2013 , 5, 575-87	17

1831	Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients. 2013 , 8, e56069	39
1830	Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. 2013 , 8, e57114	183
1829	Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. 2013 , 8, e57911	61
1828	T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. 2013 , 8, e68171	68
1827	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. 2013 , 4, 417	53
1826	Mechanisms of Metastatic Tumor Dormancy. 2013 , 2, 136-50	24
1825	Plant sterols as anticancer nutrients: evidence for their role in breast cancer. 2013 , 5, 359-87	70
1824	Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. 2013 , 2013, 835956	35
1823	Immune suppression and evasion in patients with head and neck cancer. 2013 , 1, 21809	2
1822	Immunosenescence and Senescence Immunosurveillance: One of the Possible Links Explaining the Cancer Incidence in Ageing Population. 2013 ,	1
1821	Combination Therapies to Improve Delivery of Protective T Cells into the Melanoma Microenvironment. 2013 ,	
1820	Transcriptional Modulation of Tumour Induced Angiogenesis. 2013 ,	
1819	Melanoma vaccines: trials and tribulations. 2013 , 57	8
1818	Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. 2014 , 1	1
1817	New modalities of cancer treatment for NSCLC: focus on immunotherapy. 2014 , 6, 63-75	55
1816	Avoidance of Cancer Cell Destruction by the Immune System. 2014 , 434-443	
1815	Systemic Effects of Cancer. 2014 , 456-466	2
1814	TREM-1 is induced in tumor associated macrophages by cyclo-oxygenase pathway in human non-small cell lung cancer. 2014 , 9, e94241	34

1813	Intratumoral CD8+ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. 2014 , 9, e95475	44
1812	Dendritic cell-secreted lipocalin2 induces CD8+ T-cell apoptosis, contributes to T-cell priming and leads to a TH1 phenotype. 2014 , 9, e101881	21
1811	Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer. 2014 , 9, e111494	21
1810	[The immune system - how does anti-tumor immunity arise ?]. 2014 , 37 Suppl 4, 2-5	1
1809	CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance. 2014 , 2, 841-53	15
1808	Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. 2014 , 5, 587-98	299
1807	Classification of current anticancer immunotherapies. 2014 , 5, 12472-508	301
1806	[Forward: anti-tumor immunity and tumor immunology]. 2014 , 37 Suppl 4, 1	
1805	Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. 2014 , 5, 4651-64	70
1804	Tumor plasticity interferes with anti-tumor immunity. 2014 , 34, 91-102	34
1803	Natural pattern recognition mechanisms at epithelial barriers and potential use in nanomedicine. 2014 , 6,	4
1802	Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. 2014 , 34, 399-432	11
1801	Cellular and molecular immunology of lung cancer: therapeutic implications. 2014 , 10, 1711-30	9
1800	Adding fuel to the fire: immunogenic intensification. 2014 , 10, 3306-12	3
1799	Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. 2014 , 2, 399-403	30
1798	Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. 2014 , 74, 2412-21	29
1797	The immune landscape of human tumors: Implications for cancer immunotherapy. 2014 , 3, e27456	75
1796	Prognostic value of circulating cytokines on overall survival and disease-free survival in cancer patients. 2014 , 8, 297-306	20

1795	Myeloid-derived cells are key targets of tumor immunotherapy. 2014 , 3, e28398	44
1794	Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells. 2014 , 3, e950163	43
1793	CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. 2014 , 6, 1571-84	63
1792	Past, present and future targets for immunotherapy in ovarian cancer. 2014 , 6, 1279-93	28
1791	Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. 2014 , 111, 17582-7	37
1790	Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. 2014 , 289, 33481-91	65
1789	slanDCs in carcinoma-draining lymph nodes. 2014 , 3, e28246	1
1788	Post ASCO update 2014: head and neck cancer. 2014 , 7, 231-236	1
1787	Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. 2014 , 3, e27884	61
1786	The future of glioblastoma therapy: synergism of standard of care and immunotherapy. 2014 , 6, 1953-85	51
1785	Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. 2014 , 20, 6212-22	506
1784	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. 2014 , 12, 277	10
1783	Promising new therapies in advanced pancreatic adenocarcinomas. 2014 , 10, 2629-41	10
1782	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. 2014 , 5, e1568	38
1781	Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes. 2014 , 3, e129	27
1780	Current advances in T-cell-based cancer immunotherapy. 2014 , 6, 1265-78	92
1779	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. 2014 , 111, 1350-62	15
1778	In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity. 2014 , 28, 1316-25	8

1777	Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration. 2014 , 20, 2607-2616	20
1776	API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. 2014 , 74, 3556-66	40
1775	Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. 2014 , 84, 523-35	42
1774	The impact of the TIM gene family on tumor immunity and immunosuppression. 2014 , 11, 41-8	21
1773	Overcoming tumor-mediated immunosuppression. 2014 , 6, 973-88	28
1772	Flagellin and LPS each restores rat lymphocyte populations after colorectal irradiation. 2014 , 95, 931-40	8
1771	Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity. 2014 , 2014, 175265	35
1770	Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies. 2014 , 5, 341	46
1769	Involvement of a non-human sialic Acid in human cancer. 2014 , 4, 33	95
1768	Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy. 2014 , 6, 663-83	14
1767	Vaccines against Cancer. 2014 ,	
1766	Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3 ⁺ T cells exhibit more potent immunosuppressive activity than Foxp3 ⁺ regulatory T cells. 2014 , 7, 428-39	91
1765	Orchestration of angiogenesis by immune cells. 2014 , 4, 131	74
1764	Lentiviral vector-based therapy in head and neck cancer (Review). 2014 , 7, 3-9	5
1763	Transforming growth factor- β deteriorates microrheological characteristics and motility of mature dendritic cells in concentration-dependent fashion. 2014 , 56, 25-40	9
1762	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. 2014 , 10, 1255-75	5
1761	The second annual AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology. 2014 , 2, 606-9	
1760	A <i>Drosophila</i> immune response against Ras-induced overgrowth. 2014 , 3, 250-60	31

1759	Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. 2014 , 22, 206-18	57
1758	References. 2014 , 179-224	
1757	Perspektiven für eine Immuntherapie beim hepatozellulären Karzinom. 2014 , 35, 286-290	
1756	Duality of the immune response in cancer: lessons learned from skin. 2014 , 134, E23-8	20
1755	Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?. 2014 , 2, 518-21	3
1754	New Approaches in Immunotherapy for the Treatment of Lung Cancer. 2017 , 405, 1-31	6
1753	Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. 2014 , 20, 1125-34	118
1752	Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. 2014 , 111, 14211-6	143
1751	Periodic and chaotic oscillations in a tumor and immune system interaction model with three delays. 2014 , 24, 023101	28
1750	Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. 2014 , 23, 2965-70	348
1749	Advances in Tumor Immunology and Immunotherapy. 2014 ,	0
1748	Nano-Oncologicals. 2014 ,	4
1747	Does postoperative infection after soft tissue sarcoma resection affect oncologic outcomes?. 2014 , 109, 415-20	12
1746	Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. 2014 , 134, 1810-22	36
1745	Immune regulation of bone metastasis. 2014 , 3, 600	24
1744	Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development. 2014 , 134, 849-58	25
1743	Antitumor CD8+ T cells in hepatocellular carcinoma: present but exhausted. 2014 , 59, 1232-4	14
1742	Pseudomonas aeruginosa injection enhanced antitumor cytotoxicity of cytokine-induced killer cells derived from cord blood. 2014 , 68, 1057-63	5

1741	Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers. 2014 , 257, 226-36	12
1740	PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. 2014 , 2, 1132-41	33
1739	A Systems Biology Approach to Blood. 2014 ,	2
1738	Functions of heat shock proteins in pathways of the innate and adaptive immune system. 2014 , 193, 5765-71	103
1737	Early inflammatory response in epithelial ovarian tumor cyst fluids. 2014 , 3, 1302-12	8
1736	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. 2014 , 28, 513-26	7
1735	Tumor-expressed IL-17D recruits NK cells to reject tumors. 2014 , 3, e954853	16
1734	Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. 2014 , 74, 153-161	199
1733	T cell immunosurveillance controls B lymphoma development. 2014 , 3, e28697	4
1732	Trial watch: Dendritic cell-based anticancer therapy. 2014 , 3, e963424	54
1731	Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response. 2014 , 43, 1066-72	9
1730	Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. 2014 , 3, e27588	12
1729	Latent membrane protein-specific cytotoxic T lymphocytes: new hope for patients with natural killer/T-cell lymphoma?. 2014 , 32, 2819-20	2
1728	Opioids and cancer recurrence. 2014 , 8, 91-101	50
1727	Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. 2014 , 6, 228ra37	141
1726	The immune microenvironment: a major player in human cancers. 2014 , 164, 13-26	49
1725	Tryptophan content for monitoring breast cancer cell aggressiveness by native fluorescence spectroscopy. 2014 ,	
1724	Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. 2014 , 3, e955684	36

1723	Genetic evolution of T-cell resistance in the course of melanoma progression. 2014 , 20, 6593-604	106
1722	IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers. 2014 , 74, 4908-21	25
1721	Oncolytic Adenoviruses in the Treatment of Cancer in Humans. 2014 , 153-170	
1720	Poxvirus-Based Strategies for Combined Vaccine and Tumor Microenvironment Manipulation. 2014 , 241-257	
1719	Therapeutic Efficacy and Systemic Antitumor T Cell Immunity Induced by RheoSwitch-Regulated IL-12 Expression after Intratumoral Injection of Adenovirus Vector or Vector-Transduced Dendritic Cells. 2014 , 363-376	4
1718	Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy. 2014 , 5, 438	12
1717	Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. 2014 , 14, 117	144
1716	Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice. 2014 , 192, 5434-41	14
1715	Epidemiological evidence of childhood leukaemia around nuclear power plants. 2014 , 12, 349-64	4
1714	The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. 2014 , 5, 69	48
1713	Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. 2014 , 5, 127	113
1712	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. 2014 , 2, 7	85
1711	Ephs and Ephrins in malignant gliomas. 2014 , 32, 190-201	17
1710	Pentamethoxyflavanone regulates macrophage polarization and ameliorates sepsis in mice. 2014 , 89, 109-18	36
1709	Interferons and their stimulated genes in the tumor microenvironment. 2014 , 41, 156-73	140
1708	Oncogenic transformation tunes the cross-talk between mesenchymal stem cells and T lymphocytes. 2014 , 289, 174-84	7
1707	The interplay between HPV and host immunity in head and neck squamous cell carcinoma. 2014 , 134, 2755-63	82
1706	The Yin and Yang of Toll-like receptors in cancer. 2014 , 33, 3485-95	215

1705	Harnessing the immune system for the treatment of breast cancer. 2014 , 15, 1-15	24
1704	Adoptive immunotherapy of metastatic breast cancer: present and future. 2014 , 33, 309-20	16
1703	Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. 2014 , 35, 3785-91	23
1702	Reprogramming antitumor immunity. 2014 , 35, 178-85	29
1701	New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. 2014 , 27, 16-25	882
1700	The immune system and inflammation in breast cancer. 2014 , 382, 673-682	137
1699	A dual role for autophagy in a murine model of lung cancer. 2014 , 5, 3056	296
1698	Current concepts in clinical radiation oncology. 2014 , 53, 1-29	109
1697	Tumor cell plasticity: the challenge to catch a moving target. 2014 , 49, 618-27	22
1696	Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. 2014 , 14, 48	27
1695	The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients. 2014 , 3, 3	18
1694	Tryptophan as the fingerprint for distinguishing aggressiveness among breast cancer cell lines using native fluorescence spectroscopy. 2014 , 19, 37005	19
1693	Critical role of the endogenous interferon ligand-receptors in type I and type II interferons response. 2014 , 142, 442-52	16
1692	Metastatic stem cells: sources, niches, and vital pathways. 2014 , 14, 306-21	472
1691	Immunotherapy for solid tumors--a review for surgeons. 2014 , 187, 525-35	14
1690	The immune contexture of primary and metastatic human tumours. 2014 , 27, 8-15	85
1689	Hypoxia and Cancer. 2014 ,	4
1688	The importance of animal models in tumor immunity and immunotherapy. 2014 , 24, 46-51	49

1687	Cancer Immunotherapy Meets Oncology. 2014 ,	
1686	Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. 2014 , 99, 2327-36	87
1685	The two faces of IL-6 in the tumor microenvironment. 2014 , 26, 38-47	339
1684	The ABCs of T Cell Receptor Gene Therapy. 2014 , 117-126	
1683	p53 and NF- κ B coregulate proinflammatory gene responses in human macrophages. 2014 , 74, 2182-92	103
1682	"In vitro" 3D models of tumor-immune system interaction. 2014 , 79-80, 145-54	63
1681	Imaging aspects of the tumor stroma with therapeutic implications. 2014 , 141, 192-208	44
1680	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. 2014 , 6, 459-75	76
1679	A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. 2014 , 74, 665-74	414
1678	Interplay between DNA repair and inflammation, and the link to cancer. 2014 , 49, 116-39	95
1677	Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments. 2014 , 21, 2-11	12
1676	Exosomes from myeloid-derived suppressor cells carry biologically active proteins. 2014 , 13, 836-43	105
1675	Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. 2014 , 20, 283-90	68
1674	The immune system and response to HER2-targeted treatment in breast cancer. 2014 , 15, e58-68	171
1673	Tumor-induced perturbations of cytokines and immune cell networks. 2014 , 1845, 182-201	187
1672	Immunotherapy for prostate cancer: recent developments and future challenges. 2014 , 33, 641-55	49
1671	In vivo discovery of immunotherapy targets in the tumour microenvironment. 2014 , 506, 52-7	159
1670	Association of the autoimmune disease scleroderma with an immunologic response to cancer. <i>Science</i> , 2014 , 343, 152-7	333 278

1669	Giant spin oscillations in an ultracold Fermi sea. <i>Science</i> , 2014 , 343, 157-60	33-3	41
1668	Cancer. Can cancer trigger autoimmunity?. <i>Science</i> , 2014 , 343, 147-8	33-3	8
1667	Inflammation and the two-hit hypothesis of schizophrenia. 2014 , 38, 72-93		153
1666	Beyond the cancer cell: progression-level determinants highlight the multiscale nature of carcinogenesis risk. 2014 , 74, 659-64		9
1665	Biomarkers of renal cell carcinoma. 2014 , 32, 243-51		34
1664	Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. 2014 , 21, 505-16		26
1663	Recognition of tumors by the innate immune system and natural killer cells. 2014 , 122, 91-128		233
1662	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. 2014 , 3, e22		48
1661	MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. 2014 , 20, 6034-44		92
1660	Trial Watch: Chemotherapy with immunogenic cell death inducers. 2014 , 3, e27878		116
1659	Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. 2014 , 110, 459-68		115
1658	Pathophysiology of ocular surface squamous neoplasia. 2014 , 129, 172-82		65
1657	Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity. 2014 , 281, 3882-93		9
1656	Tumors STING adaptive antitumor immunity. 2014 , 41, 679-81		13
1655	Current issues in malignant pleural mesothelioma evaluation and management. 2014 , 19, 975-84		28
1654	Infrared imaging in breast cancer: automated tissue component recognition and spectral characterization of breast cancer cells as well as the tumor microenvironment. 2014 , 139, 1044-56		55
1653	Tertiary lymphoid structures in cancer and beyond. 2014 , 35, 571-80		288
1652	Designing effective vaccines for colorectal cancer. 2014 , 6, 913-26		3

1651	EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. 2014 , 20, 972-84	205
1650	Cancer immunotherapy: hype or ripe? [corrected]. 2014 , 44, 318-20	2
1649	The presence of tumor-infiltrating IL-17-producing cells in juvenile nasopharyngeal angiofibroma tumor microenvironment is a poor prognostic factor. 2014 , 35, 582-8	6
1648	Immune approaches to the treatment of breast cancer, around the corner?. 2014 , 16, 204	33
1647	Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. 2014 , 2, 404-9	7
1646	Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. 2014 , 11, 495-502	66
1645	Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. 2014 , 111, 5998-6003	53
1644	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. 2014 , 20, 1301-9	596
1643	The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. 2014 , 2, 187-93	156
1642	Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. 2014 , 74, 5978-88	24
1641	Establishment of tumor-associated immunity requires interaction of heat shock proteins with CD91. 2014 , 2, 217-28	27
1640	Translational biology of osteosarcoma. 2014 , 14, 722-35	644
1639	STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. 2014 , 2, 1199-208	128
1638	Signal Molecule-Calcium Phosphate Composites: Novel Approaches to Controlling Cellular and/or Biological Reactions and Functions. 2014 , 171-197	
1637	New strategies in lung cancer: translating immunotherapy into clinical practice. 2014 , 20, 1067-73	36
1636	Impact of myeloid cells on the efficacy of anticancer chemotherapy. 2014 , 30, 24-31	28
1635	Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia. 2014 , 354, 281-9	18
1634	Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting. 2014 , 22, 167-75	6

1633 Chimeric Antigen Receptors CARs 2014, 519-560

1632 Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials. 2014, 735-786

1631 Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. 2014, 74, 5746-57 122

1630 Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model. 2014, 36, 827-35 42

1629 The gut microbiota, bacterial metabolites and colorectal cancer. 2014, 12, 661-72 1390

1628 NF- κ B functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells. 2014, 9, 90-103 45

1627 Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study. 2014, 14, 486 59

1626 Adoptive T-cell therapy for Leukemia. 2014, 2, 25 13

1625 Hashimoto's thyroiditis pathology and risk for thyroid cancer. 2014, 24, 1107-14 52

1624 The role of microRNAs in the control of innate immune response in cancer. 2014, 106, 50

1623 Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. 2014, 147, 227-35 16

1622 Stromal fibroblasts and the immune microenvironment: partners in mammary gland biology and pathology?. 2014, 19, 169-82 25

1621 Human hepatocellular carcinoma-infiltrating CD4+CD69+Foxp3⁺ regulatory T cell suppresses T cell response via membrane-bound TGF- β . 2014, 92, 539-50 27

1620 PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. 2014, 63, 395-406 111

1619 Resveratrol-induced potentiation of the antitumor effects of oxaliplatin is accompanied by an altered cytokine profile of human monocyte-derived macrophages. 2014, 19, 1136-47 13

1618 Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine. 2014, 2, 6 7

1617 Ovalbumin lipid core peptide vaccines and their CD4(+) and CD8(+) T cell responses. 2014, 32, 4743-50 11

1616 Tumor antigen discovery through translation of the cancer genome. 2014, 58, 292-9 8

1615	Prognostic value of tumor-infiltrating mast cells in outcome of patients with esophagus squamous cell carcinoma. 2014 , 45, 48-53	16
1614	Cancer cell resistance mechanisms: a mini review. 2014 , 16, 511-6	42
1613	Monoklonale Antikörper in der Onkologie. 2014 , 29, 112-118	
1612	Immunocompetent murine models for the study of glioblastoma immunotherapy. 2014 , 12, 107	131
1611	Jaagsiekte sheep retrovirus detected in human lung cancer tissue arrays. 2014 , 7, 160	16
1610	Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. 2014 , 110, 1595-605	203
1609	Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system. 2014 , 74, 1335-46	29
1608	In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. 2014 , 20, 2773-82	337
1607	Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. 2014 , 134, 1823-34	15
1606	Characteristics and significance of colorectal cancer associated lymphoid reaction. 2014 , 134, 2126-35	75
1605	Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. 2014 , 7, 989-98	57
1604	[Immunotherapy in epithelial ovarian carcinoma: hope and reality]. 2014 , 43, 198-210	1
1603	Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. 2014 , 161, 20-30	17
1602	Complex adaptive therapeutic strategy (CATS) for cancer. 2014 , 175, 43-7	19
1601	Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?. 2014 , 32, 4015-24	21
1600	Host immune response to infection and cancer: unexpected commonalities. 2014 , 15, 295-305	99
1599	Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. 2014 , 2, 741-55	93
1598	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. 2014 , 25, 1544-50	780

1597	Paraneoplasia, cancer development and immunity: what are the connections?. 2014 , 14, 447-8	2
1596	T-cell epitope discovery technologies. 2014 , 75, 514-9	9
1595	Introduction to the role of the immune system in melanoma. 2014 , 28, 537-58	7
1594	Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. 2014 , 89, 504-19	63
1593	Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. 2014 , 2, 105	125
1592	[Immunology and personalized medicine in oncology]. 2014 , 101 Suppl 1, S12-7	1
1591	Promises and Challenges with Immunomodulatory Biologics. 2014 , 159-188	
1590	The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers. 2014 , 44, 1461-9	43
1589	[Intratumoral immune microenvironment and survival: the immunoscore]. 2014 , 30, 439-44	15
1588	Overcoming immune system evasion by personalized immunotherapy. 2014 , 11, 561-564	
1587	Les lymphocytes Th17 intra-tumoraux exercent des fonctions immunosuppressives dépendantes de l'adénosine chez les patientes porteuses de cancers du sein. 2015 , 99, 153	
1586	T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN- γ Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma. 2015 , 13, 2470-2479	31
1585	A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphoma. 2015 , 48, 453-64	12
1584	Immunotherapy of Brain Tumors. 2015 , 42, 11-21	6
1583	Immunosuppressant-driven de novo malignant neoplasms after solid-organ transplant. 2015 , 25, 182-8	21
1582	Peripheral blood cells inform on the presence of breast cancer: a population-based case-control study. 2015 , 136, 656-67	17
1581	Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. 2015 , 146, 33-49	5
1580	Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer. 2015 , 6, 613-9	8

1579	Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis. 2015 , 37, 1560-71	146
1578	Modulation of dendritic cell function by the radiation-mediated secretory protein β synuclein. 2015 , 1, 15011	8
1577	Intratumoral INF- γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer. 2015 , 2, 15009	3
1576	Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis. 2015 , 5, 11026	63
1575	Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. 2015 , 10, 974-84	86
1574	Principles of Targeted Immunotherapy. 2015 , 27-38	
1573	Transmembrane protein 106a activates mouse peritoneal macrophages via the MAPK and NF- κ B signaling pathways. 2015 , 5, 12461	14
1572	Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. 2015 , 34, 2042-58	69
1571	Anticoagulation. 47-52	
1570	Cancer pain. 85-90	
1569	Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer. 2015 , 15, 899-907	60
1568	Targeting Breast Cancer Metastasis. 2015 , 9, 23-34	87
1567	Emerging immunotherapies for bladder cancer. 2015 , 27, 191-200	21
1566	Whole-Blood Gene Expression Profiles in Large-Scale Epidemiological Studies: What Do They Tell?. 2015 , 4, 377-386	10
1565	Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. 2015 , 4, 365-375	1
1564	Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model. 2015 , 5, 47	1
1563	The role of chemotherapy and operation on lymphocytes accumulation in peripheral blood obtained from patients with oral squamous cell carcinoma. 2015 , 4, 698	1
1562	An der Schwelle zu einem neuen Zeitalter. 2015 , 18, 96-97	

1561	Primary pulmonary melanoma: a report of two cases. 2015 , 13, 274	9
1560	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. 2015 , 13, 217	30
1559	Risk of cancer of unknown primary after hospitalization for autoimmune diseases. 2015 , 137, 2885-95	11
1558	Can Peto's paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. 2015 , 15, 792	11
1557	Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. 2015 , 34, 108	43
1556	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. 2015 , 121, 2968-75	17
1555	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. 2015 , 9, 31-8	19
1554	Pharmacological inhibition of caspase-8 limits lung tumour outgrowth. 2015 , 172, 3917-28	11
1553	Endogenous immunity at the forefront of tumor dormancy. 2015 , 1, FSO13	2
1552	Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrences in orthotopic xenograft models of pancreatic cancer. 2015 , 137, 1035-46	74
1551	Which is a more reliable indicator of survival after gastric cancer surgery: Postoperative complication occurrence or C-reactive protein elevation?. 2015 , 112, 894-9	49
1550	Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. 2015 , 62, 1326-36	9
1549	Brief Report: Human Mesenchymal Stem-Like Cells Facilitate Floating Tumorigenic Cell Growth via Glutamine-Ammonium Cycle. 2015 , 33, 2877-84	5
1548	Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. 2015 , 45, 755-63	18
1547	Procalcitonin as a biomarker for infection-related mortality in cancer patients. 2015 , 9, 168-73	6
1546	Nanogel-Incorporated Physical and Chemical Hybrid Gels for Highly Effective ChemoProtein Combination Therapy. 2015 , 25, 6744-6755	77
1545	Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. 2015 , 35, 963-76	140
1544	Immunotherapies for bladder cancer: a new hope. 2015 , 25, 586-96	13

1543	Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions. 2015 , 21, 450-64	30
1542	Lymphoma: immune evasion strategies. 2015 , 7, 736-62	29
1541	B Cell Epitope-Based Vaccination Therapy. 2015 , 4, 225-239	8
1540	Polarization and Repolarization of Macrophages. 2015 , 06,	14
1539	Adoptive T cell immunotherapy for cancer. 2015 , 6, e0004	131
1538	Tumor neoantigens: building a framework for personalized cancer immunotherapy. 2015 , 125, 3413-21	370
1537	Cancer immunotherapy: harnessing the immune system to battle cancer. 2015 , 125, 3335-7	597
1536	Current Preclinical Models of Ovarian Cancer. 2015 , 06,	3
1535	Tumor associated antigens and its potential use in cancer therapy. 2015 , 31, 118-137	
1534	MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer. 2015 , 6, 10284-96	38
1533	Stem Cell Therapy for Brain Tumors. 2015 , 2015, 67-106	1
1532	Immunopathogenesis of Colitis-Associated Cancer in an Animal Model. 2015 , 25, 245-51	2
1531	Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. 2015 , 3, 420-8	14
1530	Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. 2015 , 3, 597-619	38
1529	Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches. 2015 , 7, 585-97	7
1528	Mining the Dynamic Genome: A Method for Identifying Multiple Disease Signatures Using Quantitative RNA Expression Analysis of a Single Blood Sample. 2015 , 4, 671-89	5
1527	A Quantitative Systems Pharmacology Perspective on Cancer Immunology. 2015 , 3, 235-256	7
1526	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. 2015 , 6, 402	84

1525	Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress. 2015 , 6, 482	82
1524	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. 2015 , 6, 505	71
1523	Immunotherapy of Childhood Sarcomas. 2015 , 5, 181	44
1522	Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia. 2015 , 3, 80	15
1521	"Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy. 2015 , 2015, 869547	8
1520	Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways. 2015 , 10, e0126466	22
1519	Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer. 2015 , 10, e0143370	28
1518	Therapeutic strategy for cancer immunotherapy in head and neck cancer. 2015 , 3, 27690	4
1517	Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis. 2015 , 70, 524-30	95
1516	Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. 2015 , 4, 157-67	11
1515	Effect of Propofol and Desflurane on Immune Cell Populations in Breast Cancer Patients: A Randomized Trial. 2015 , 30, 1503-8	30
1514	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. 2015 , 2015, 191832	40
1513	Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. 2015 , 2015, 308574	23
1512	Clinical Development of Immune Checkpoint Inhibitors. 2015 , 2015, 605478	46
1511	Vaccines for TB: Lessons from the Past Translating into Future Potentials. 2015 , 2015, 916780	6
1510	Current Concept and Update of the Macrophage Plasticity Concept: Intracellular Mechanisms of Reprogramming and M3 Macrophage "Switch" Phenotype. 2015 , 2015, 341308	120
1509	From mice to humans: developments in cancer immunoediting. 2015 , 125, 3338-46	188
1508	Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma. 2015 , 6, 44806-18	2

1507	Immunoediting, Immunosurveillance, Tumor-induced Immunosuppression and Immuno-resistance, Immunomodulation, Immunotherapy, and Immunonutrition in Personalized and Precision Cancer Medicine. 2015,		
1506	Principles of Cancer Immunobiology and Immunotherapy of Solid Tumors. 2015,		3
1505	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. 2015, 6, 15772-87		197
1504	The potential of Src inhibitors. 2015, 7, 734-5		17
1503	Immunopathology and Immunotherapy of Central Nervous System Cancer. 2015, 333-362		1
1502	T cell exclusion, immune privilege, and the tumor microenvironment. <i>Science</i> , 2015, 348, 74-80	33.3	1156
1501	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. 2015, 33, 2780-8		1480
1500	Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. 2015, 49, 907-37		118
1499	Programmed death-1 checkpoint blockade in acute myeloid leukemia. 2015, 15, 1191-203		50
1498	Methods to study tumor surveillance using tumor cell transplantation into genetically engineered mice. 2015, 1267, 439-56		
1497	Type I interferons in anticancer immunity. 2015, 15, 405-14		606
1496	Alcohol consumption and antitumor immunity: dynamic changes from activation to accelerated deterioration of the immune system. 2015, 815, 313-31		9
1495	Development of Personalized Combination Cancer Immunotherapy Based on the Patients' Immune Status. 2015, 255-266		2
1494	MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. 2015, 94, 31-44		52
1493	Theoretical considerations for thresholds in chemical carcinogenesis. 2015, 765, 56-67		25
1492	Shenling Baizhu San suppresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration. 2015, 15, 126		23
1491	Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor progression. 2015, 75, 813-23		71
1490	Cancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape. 2015, 195-208		2

1489	Immunology and Immunotherapy of Colorectal Cancer. 2015 , 217-236	2
1488	Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. 2015 , 365, 23-9	70
1487	T-Cell Immunotherapy for Cancer. 2015 , 389-410	
1486	On the apparent rarity of epithelial cancers in captive chimpanzees. 2015 , 370,	22
1485	Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure. 2015 , 75, 3032-42	3
1484	Pseudoprogession and Immune-Related Response in Solid Tumors. 2015 , 33, 3541-3	555
1483	Immunotherapy of Breast Cancer. 2015 , 42, 30-43	25
1482	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. 2015 , 28, 690-714	828
1481	Developments in T Cell Based Cancer Immunotherapies. 2015 ,	
1480	Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP100(25-33) peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma. 2015 , 468, 46-52	4
1479	Systematic pan-cancer analysis of tumour purity. 2015 , 6, 8971	555
1478	Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. 2015 , 5, e006404	95
1477	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. 2015 , 5, 257-267	
1476	Current and Emerging Perspectives on Immunotherapy for Melanoma. 2015 , 42 Suppl 3, S3-S11	17
1475	Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. 2015 , 3,	8
1474	Intravital imaging of multicolor-labeled tumor immune microenvironment through skin-fold window chamber. 2015 ,	
1473	Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. 2015 , 10, 3411-3418	37
1472	Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer. 2015 , 8, 339-45	132

1471	Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies. 2015 , 245-258	
1470	Curcumin and tumor immune-editing: resurrecting the immune system. 2015 , 10, 6	79
1469	STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?. 2015 , 11, 155-65	17
1468	Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. 2015 , 41, 61-8	42
1467	Targeting the tumor vasculature to enhance T cell activity. 2015 , 33, 55-63	169
1466	Trial Watch: Peptide-based anticancer vaccines. 2015 , 4, e974411	81
1465	Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells. 2015 , 3, 116-24	25
1464	Monocyte-derived dendritic cells reflect the immune functional status of a chromophobe renal cell carcinoma patient: could it be a general phenomenon?. 2015 , 64, 161-71	6
1463	Mouse Models of Cancer. 2015 ,	2
1462	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. 2015 , 25, 208-24	126
1461	Immune escape mechanisms as a guide for cancer immunotherapy. 2015 , 21, 687-92	523
1460	Radiation meets immunotherapy - a perfect match in the era of combination therapy?. 2015 , 91, 299-305	17
1459	VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. 2015 , 212, 139-48	556
1458	Gain of HIF-1 α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes. 2015 , 21, 1438-46	38
1457	Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment. 2015 , 23, 396-406	18
1456	Molecular and genetic properties of tumors associated with local immune cytolytic activity. 2015 , 160, 48-61	1834
1455	Exploiting the critical perioperative period to improve long-term cancer outcomes. 2015 , 12, 213-26	248
1454	Building immunity to cancer with radiation therapy. 2015 , 368, 198-208	57

1453	Microsatellite instability: an update. 2015 , 89, 899-921	118
1452	Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy. 2015 , 93, 323-5	8
1451	Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics. 2015 , 194, 2049-56	92
1450	Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. 2015 , 17, 6	36
1449	Interleukin-23 promotes the epithelial-mesenchymal transition of oesophageal carcinoma cells via the Wnt/ β -catenin pathway. 2015 , 5, 8604	32
1448	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. 2015 , 16, 257-65	1050
1447	Prostate cancer vaccines: the long road to clinical application. 2015 , 64, 401-8	16
1446	Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. 2015 , 64, 493-505	17
1445	Biomarkers for glioma immunotherapy: the next generation. 2015 , 123, 359-72	20
1444	Nivolumab in NSCLC: latest evidence and clinical potential. 2015 , 7, 85-96	164
1443	The role of oncolytic virus immunotherapies to subvert cancer immune evasion. 2015 , 11, 675-89	15
1442	The yin and yang of evasion and immune activation in HCC. 2015 , 62, 1420-9	177
1441	Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy. 2015 , 7, 278ra34	58
1440	The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. 2015 , 16, 225-38	889
1439	Glioblastoma antigen discovery--foundations for immunotherapy. 2015 , 123, 347-58	6
1438	Combination cancer immunotherapy and new immunomodulatory targets. 2015 , 14, 561-84	806
1437	Activation of mucosal mast cells promotes inflammation-related colon cancer development through recruiting and modulating inflammatory CD11b(+)/Gr1(+) cells. 2015 , 364, 173-80	18
1436	Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. 2015 , 112, 9967-72	27

1435	Macrophage polarization in pathology. 2015 , 72, 4111-26	337
1434	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. 2015 , 113, 786-93	16
1433	Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. 2015 , 113, 232-41	80
1432	The MAPK-Activated Kinase MK2 Attenuates Dendritic Cell-Mediated Th1 Differentiation and Autoimmune Encephalomyelitis. 2015 , 195, 541-52	15
1431	Challenges and future perspectives of T cell immunotherapy in cancer. 2015 , 166, 117-33	37
1430	Unknown primary of the head and neck: A long-term follow-up. 2015 , 43, 574-9	8
1429	Tumor Immunotherapy of Esophageal and Gastric Cancers. 2015 , 185-197	
1428	Engineering cancer microenvironments for 3-D tumor models. 2015 , 18, 539-553	197
1427	Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia. 2015 , 134, 255-62	31
1426	Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer. 2015 , 3, 1279-88	3
1425	Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?. 2015 , 5, 250-256	6
1424	Engineered Materials for Cancer Immunotherapy. 2015 , 10, 511-531	76
1423	Concepts of immunotherapy for glioma. 2015 , 123, 323-30	12
1422	Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. 2015 , 13, 49-54	33
1421	Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy. 2015 , 107,	55
1420	IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. 2015 , 21, 719-29	488
1419	Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. 2015 , 6, 46	60
1418	NANOG signaling promotes metastatic capability of immunoedited tumor cells. 2015 , 32, 429-39	11

1417	Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. 2015 , 521, 99-104	124
1416	Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. 2015 , 15, 509-23	18
1415	Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications. 2015 , 34, 123-33	20
1414	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. 2015 , 24, 290-3	18
1413	Neoantigens in cancer immunotherapy. <i>Science</i> , 2015 , 348, 69-74	33-3 2790
1412	Pembrolizumab for the treatment of non-small-cell lung cancer. 2015 , 372, 2018-28	3943
1411	The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β -glucan. 2015 , 69, 198-208	11
1410	Precision immunology: the promise of immunotherapy for the treatment of cancer. 2015 , 33, 1315-7	9
1409	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. 2015 , 17, 18	17
1408	Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. 2015 , 16, 64	329
1407	Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. 2015 , 42, 767-77	97
1406	Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. 2015 , 149, 201-10	182
1405	Man is the new mouse: Elective surgery as a key translational model for multi-organ dysfunction and sepsis. 2015 , 16, 154-163	2
1404	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. 2015 , 3, 399-411	289
1403	Immunotherapy for canine cancer--is it time to go back to the future?. 2015 , 56, 229-41	7
1402	Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. 2015 , 15, 101	60
1401	Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. 2015 , 15, 356	40
1400	Enzyme-instructed self-assembly: a multistep process for potential cancer therapy. 2015 , 26, 987-99	102

1399	Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer. 2015 , 33, 969-71	25
1398	Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model. 2015 ,	13
1397	Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015 , 348, 124-8	33.3 5003
1396	Overcoming T cell exhaustion in infection and cancer. 2015 , 36, 265-76	619
1395	Role of tumor-associated glycoprotein-72 in the progression of endometrial adenocarcinoma: a proposed study. 2015 , 84, 413-6	1
1394	Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. 2015 , 21, 1127-38	45
1393	Inflammation and Immunity in Cancer. 2015 ,	1
1392	Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. 2015 , 21, 976-84	155
1391	Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs. 2015 , 194, 5529-38	97
1390	Immune Therapy in GI Malignancies: A Review. 2015 , 33, 1745-53	29
1389	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. 2015 , 125, 2077-89	69
1388	Synthetic immunity to break down the bottleneck of cancer immunotherapy. 2015 , 60, 977-985	2
1387	A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. 2015 , 112, 1215-22	44
1386	PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. 2015 , 126, 203-11	135
1385	Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. 2015 , 94, e639	42
1384	Gene expression. MicroRNA control of protein expression noise. <i>Science</i> , 2015 , 348, 128-32	33.3 252
1383	Autophagy, cell death, and cancer. 2015 , 2, e985913	118
1382	Photodynamic therapy-mediated cancer vaccination enhances stem-like phenotype and immune escape, which can be blocked by thrombospondin-1 signaling through CD47 receptor protein. 2015 , 290, 8975-86	14

1381	Risk of Overall and Site-specific Cancers in Behçet Disease: A Nationwide Population-based Study in Taiwan. 2015 , 42, 879-84	26
1380	The journey from discoveries in fundamental immunology to cancer immunotherapy. 2015 , 27, 439-49	157
1379	Targeting the immune system to treat lung cancer: rationale and clinical experience. 2015 , 9, 105-20	11
1378	Therapeutic Impact of Immune Responses in Cancer. 2015 , 221-245	
1377	Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset. 2015 , 4, e1034918	34
1376	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. 2021 , 1-14	18
1375	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. 2015 , 3, 1344-55	197
1374	Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients. 2015 , 16, 743-56	7
1373	Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells. 2015 , 195, 4028-37	18
1372	Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model. 2015 , 135, 2785-2793	15
1371	Relevance of tumor-infiltrating lymphocytes in breast cancer. 2015 , 13, 202	131
1370	Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. 2015 , 13, 493-501	48
1369	Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. 2015 , 17, 1675-86	23
1368	Increased tumor infiltration by mucosal-associated invariant T cells correlates with poor survival in colorectal cancer patients. 2015 , 64, 1601-8	66
1367	Minimal residual disease in cancer therapy--Small things make all the difference. 2015 , 21-22, 1-10	19
1366	Multifunctional T Lymphocytes Generated After Therapy With an Antitumor Gallotannin-Rich Normalized Fraction Are Related to Primary Tumor Size Reduction in a Breast Cancer Model. 2015 , 14, 468-83	20
1365	Head and Neck Cancer Stem Cells: From Identification to Tumor Immune Network. 2015 , 94, 1524-31	25
1364	Myeloid promotes formation of colitis-associated colorectal cancer in mice. 2015 , 4, e998529	19

1363	Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?. 2015 , 11, 2645-2654	26
1362	Loss of PTEN causes SHP2 activation, making lung cancer cells unresponsive to IFN- γ . 2015 , 466, 578-84	14
1361	CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation. 2015 , 45, 71-81	23
1360	Natural and therapy-induced immunosurveillance in breast cancer. 2015 , 21, 1128-38	196
1359	Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. 2015 , 26, 2429-36	82
1358	CANCER. The odds of immunotherapy success. <i>Science</i> , 2015 , 350, 158-9	333 70
1357	Genetic instability in the tumor microenvironment: a new look at an old neighbor. 2015 , 14, 145	41
1356	Congrès de l'association américaine de recherche contre le cancer [AACR 2015]. 2015 , 17, 277-298	
1355	Immunogénéité de la chimiothérapie. 2015 , 17, 345-353	
1354	Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete Resection. 2015 , 22 Suppl 3, S1324-31	59
1353	The Dynamics of Interactions Among Immune and Glioblastoma Cells. 2015 , 17, 335-52	21
1352	Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity. 2015 , 21, 5380-90	12
1351	The correlation between the metabolic tumor volume and hematological parameters in patients with esophageal cancer. 2015 , 29, 906-10	10
1350	Diversity index of mucosal resident T lymphocyte repertoire predicts clinical prognosis in gastric cancer. 2015 , 4, e1001230	41
1349	CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer. 2015 , 75, 4074-85	82
1348	Adaptive Immune Resistance: How Cancer Protects from Immune Attack. 2015 , 5, 915-9	360
1347	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. 2015 , 162, 974-86	872
1346	Are BiTEs the "missing link" in cancer therapy?. 2015 , 4, e1008339	49

1345	Role of the Tumor Microenvironment in Breast Cancer. 2015 , 82, 142-52	185
1344	Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities. 2015 , 7, 883-2	16
1343	The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity. 2015 , 43, 751-63	171
1342	Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. 2015 , 33, 1152-8	359
1341	Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. 2015 , 33, 4015-22	691
1340	Activation and Exhaustion of Adaptive Immune Cells in Hepatitis B Infection. 2015 , 28, 348-53	8
1339	Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. 2015 , 162, 1257-70	602
1338	Trial watch: Naked and vectored DNA-based anticancer vaccines. 2015 , 4, e1026531	22
1337	Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. 2015 , 42, 562-72	28
1336	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. 2015 , 7, 1169-86	35
1335	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. 2015 , 9, 2054-62	60
1334	Interferons. 2015 , 739-752.e7	1
1333	Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. 2015 , 1855, 61-82	43
1332	Immunotherapy for malignant gliomas. 2015 , 163, 143-58	9
1331	PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. 2015 , 75, 508-518	133
1330	Radiation and inflammation. 2015 , 25, 4-10	133
1329	Review: cancer-induced autoimmunity in the rheumatic diseases. 2015 , 67, 317-26	70
1328	On the interplay between mathematics and biology: hallmarks toward a new systems biology. 2015 , 12, 44-64	40

1327	Current Understanding and Treatment of Gliomas. 2015,	5
1326	Biological Basis of Alcohol-Induced Cancer. 2015,	3
1325	Nanoparticle-based immunotherapy for cancer. 2015, 9, 16-30	322
1324	Genomic Instability and Cancer Metastasis. 2015,	1
1323	Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. 2015, 6, 275-87	64
1322	Smoking and body mass index as risk factors for subtypes of cancer of unknown primary. 2015, 136, 246-7	19
1321	Advances in the understanding of cancer immunotherapy. 2015, 116, 321-9	20
1320	NKG2D signaling in cancer immunosurveillance. 2015, 136, 1741-50	88
1319	The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. 2015, 8, 125-58	227
1318	The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. 2015, 45, 17-31	143
1317	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. 2015, 27, 39-46	222
1316	Stress Response Pathways in Cancer. 2015,	3
1315	Intratumoural inflammation and endocrine resistance in breast cancer. 2015, 22, R51-67	17
1314	Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. 2015, 64, 51-9	54
1313	Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN γ -dependent cell-cycle arrest. 2015, 3, 26-36	56
1312	Novel points of attack for targeted cancer therapy. 2015, 116, 9-18	34
1311	Immune evasion through competitive inhibition: the shielding effect of cancer non-stem cells. 2015, 364, 40-8	16
1310	Tumor-Associated Macrophages. 2016, 493-498	0

1309	Neoantigen-based cancer immunotherapy. 2016 , 4, 262	55
1308	Combining Immunotherapies with Standard Therapies in the Treatment of Cancer. 2016 , 569-580	
1307	Immuno-oncology combinations: raising the tail of the survival curve. 2016 , 13, 171-93	67
1306	Regulatory T Cells in Tumor Immunity. 2016 , 451-459	2
1305	Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. 2016 , 9, 2649-54	25
1304	FTIR imaging of MCF-7 colonies and their vicinity in Matrigel-embedded 3D cultures. 2016 , 5, 155-166	1
1303	Ocular Surface Squamous Cell Carcinoma with Intraorbital Extension in a Patient with Long-Term Immunosuppression. 2016 , 57, 507	
1302	Importance of tumor infiltrating lymphocytes in non-small cell lung cancer?. 2016 , 4, 142	5
1301	Immunosuppressive Environment in Basal Cell Carcinoma: The Role of Regulatory T Cells. 2016 , 96, 917-921	28
1300	Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. 2016 , 22, 557-66	179
1299	Chronic Inflammation in Skin Malignancies. 2016 , 11, 2	26
1298	Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. 2016 , 12, 23-36	
1297	NK Cells in Antitumor Immunity. 2016 , 487-492	
1296	The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. 2016 , 2016, 6829283	15
1295	Immunological battlefield in gastric cancer and role of immunotherapies. 2016 , 22, 6373-84	22
1294	Improving the clinical impact of biomaterials in cancer immunotherapy. 2016 , 7, 15421-43	43
1293	Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. 2016 , 7, 39885-39893	21
1292	Basic Overview of Current Immunotherapy Approaches in Cancer. 2016 , 35, 298-308	63

1291	Emerging Therapeutic Options for HER2-Positive Breast Cancer. 2016 , 35, e64-70	15
1290	Immunoproteasome deficiency in non-small cell lung cancer and its relevance to immunotherapy. 2016 , 8, E1082-E1086	2
1289	Tumor lymphocytic infiltration in non-small cell lung cancer: the ultimate prognostic marker?. 2016 , 5, 370-2	4
1288	Role of Autophagy in Cancer Therapy. 2016 , 231-251	
1287	Metastatic spread in patients with gastric cancer. 2016 , 7, 52307-52316	158
1286	The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. 2016 , 2016, 4273943	106
1285	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. 2016 , 2016, 4683607	29
1284	Bacteria in Cancer Therapy: Renaissance of an Old Concept. 2016 , 2016, 8451728	79
1283	Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy. 2016 , 5,	29
1282	Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease. 2016 , 2016, 4375120	22
1281	The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer. 2016 , 9, 6529-6537	36
1280	Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy. 2016 , 8,	5
1279	Potential role of immunotherapy in advanced non-small-cell lung cancer. 2017 , 10, 21-30	33
1278	In Vivo Visualization of Tumor Antigen-containing Microparticles Generated in Fluorescent-protein-elicited Immunity. 2016 , 6, 1453-66	15
1277	Inflammation and Cancer. 2016 , 406-415	7
1276	The emerging role of immunotherapy in colorectal cancer. 2016 , 4, 305	49
1275	Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. 2016 , 4, 64	22
1274	The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. 2016 , 4,	30

1273	Non-small cell lung cancer: current treatment and future advances. 2016 , 5, 288-300	762
1272	A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. 2016 , 7, 109	210
1271	Tertiary Lymphoid Organs in Cancer Tissues. 2016 , 7, 244	57
1270	Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma. 2016 , 6, 134	2
1269	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. 2016 , 6, 256	28
1268	Cancer Immunosurveillance: Immunoediting. 2016 , 396-405	3
1267	Advances in Cancer Immunotherapy in Solid Tumors. 2016 , 8,	109
1266	The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. 2016 , 17,	24
1265	A Novel Inflammation-Based Stage (I Stage) Predicts Overall Survival of Patients with Nasopharyngeal Carcinoma. 2016 , 17,	24
1264	Mechanisms of Immune Escape in Cancer. 2016 , 75, 152-155	
1263	MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. 2016 , 11, e0145920	26
1262	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. 2016 , 11, e0163138	8
1261	Human Leukocyte Antigen G Polymorphism and Expression Are Associated with an Increased Risk of Non-Small-Cell Lung Cancer and Advanced Disease Stage. 2016 , 11, e0161210	9
1260	Clinical Characteristics of Malignant Melanoma in Southwest China: A Single-Center Series of 82 Consecutive Cases and a Meta-Analysis of 958 Reported Cases. 2016 , 11, e0165591	15
1259	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. 2016 , 9, 5101-16	26
1258	Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. 2016 , 9, 4805-13	29
1257	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. 2016 , 2, 15-25	21
1256	Systemic and intratumoral balances between monocytes/macrophages and lymphocytes predict prognosis in hepatocellular carcinoma patients after surgery. 2016 , 7, 30951-61	24

1255	Current and emerging therapies in unresectable and recurrent gastric cancer. 2016 , 22, 4812-23	40
1254	Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma. 2016 , 95, e2722	34
1253	Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. 2016 , 22, 101-7	17
1252	Immune Checkpoint Therapy in Head and Neck Cancers. 2016 , 22, 108-16	10
1251	Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis. 2016 , 272, 169-82	9
1250	Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+);LSL-Trp53(R172H/+);Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. 2016 , 73, 14.39.1-14.39.20	88
1249	TIL 2.0: More effective and predictive T-cell products by enrichment for defined antigen specificities. 2016 , 46, 1335-9	6
1248	Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis. 2016 , 68, 2394-402	14
1247	Cancer Vaccines: Past, Present, and Future. 2016 , 23, 180-91	14
1246	Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. 2016 , 38, 201-7	1
1245	Computational genomics tools for dissecting tumour-immune cell interactions. 2016 , 17, 441-58	172
1244	Pollinosis and all-cause mortality among middle-aged and elderly Japanese: a population-based cohort study. 2016 , 46, 1083-9	5
1243	Comprehensive Mechanism Analysis of Mesoporous-Silica-Nanoparticle-Induced Cancer Immunotherapy. 2016 , 5, 1169-76	49
1242	The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer. 2016 , 139, 112-21	39
1241	Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer. 2016 , 11, 3975-3981	30
1240	Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma. 2016 , 64, 828-42	18
1239	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. 2016 , 30, 120-135	200
1238	Immunotherapy for genitourinary cancer: state of the art and new perspectives. 2016 , 27, 585-99	4

1237	Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. 2016 , 63, 1888-99	30
1236	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. 2016 , 5, e1186323	2
1235	Inflammatory Immune Infiltration in Human Tumors: Role in Pathogenesis and Prognostic and Diagnostic Value. 2016 , 81, 1261-1273	8
1234	Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy. 2016 , 5, 567-574	39
1233	Cancer Immunotherapy for Gliomas: Overview and Future Directions. 2016 , 56, 355-60	4
1232	Biochemistry of Oxidative Stress. 2016 ,	3
1231	Immune checkpoint inhibitors renal side effects and management. 2016 , 8, 1417-1425	8
1230	Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. 2016 , 6, 21319	50
1229	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. 2016 , 4, 90	14
1228	Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. 2016 , 11, 2048-2050	34
1227	Tumor-Induced Myeloid-Derived Suppressor Cells. 2016 , 4,	21
1226	Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. 2016 , 128, 3113-3124	81
1225	Cancer Prevention: Lessons Learned and Future Directions. 2016 , 2, 713-722	11
1224	Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. 2016 , 7, 12258	55
1223	Assession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. 2016 , 62, 1504-1515	99
1222	Location of metastases in cancer of unknown primary are not random and signal familial clustering. 2016 , 6, 22891	13
1221	Checkpoint inhibition in myeloma. 2016 , 2016, 528-533	8
1220	STAT1-associated intratumoural T1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. 2016 , 2, 259-270	28

1219	Mechanisms of tumour escape from immune surveillance. 2016 , 60, 453-460	9
1218	Lymphangioma-like Kaposi Sarcoma in Transplant-Associated Iatrogenic Immunosuppression: A Case Report. 2016 , 48, 3134-3136	3
1217	GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells. 2016 , 5, e119	20
1216	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. 2016 , 5, e1240857	40
1215	The Evolving, Multifaceted Roles of Autophagy in Cancer. 2016 , 130, 1-53	40
1214	Immune checkpoint inhibitors in lung cancer: past, present and future. 2016 , 12, 1151-63	24
1213	An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. 2016 , 59, 379-85	12
1212	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. 2016 , 5, e1160193	9
1211	The importance of being a regulatory T cell in pregnancy. 2016 , 116, 60-9	31
1210	Emerging immunotherapies for glioblastoma. 2016 , 21, 133-45	29
1209	mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70). 2016 , 1428, 277-83	3
1208	Inflammation Mediated by JNK in Myeloid Cells Promotes the Development of Hepatitis and Hepatocellular Carcinoma. 2016 , 15, 19-26	48
1207	Synthetic mRNA. 2016 ,	0
1206	Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated V α 4 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells. 2016 , 6, 213-27	48
1205	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. 2016 , 13, 674-690	1246
1204	Combinatorial Cancer Immunotherapies. 2016 , 130, 251-77	75
1203	The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma. 2016 , 31-65	
1202	Ovarian cancer and the immune system - The role of targeted therapies. 2016 , 142, 349-56	41

1201	CIS is a potent checkpoint in NK cell-mediated tumor immunity. 2016 , 17, 816-24	185
1200	FoxO1 regulates apoptosis induced by asbestos in the MT-2 human T-cell line. 2016 , 13, 620-7	14
1199	Reducing prostaglandin E2 production to raise cancer immunogenicity. 2016 , 5, e1123370	11
1198	The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. 2016 , 46, 9-19	60
1197	Les anticorps monoclonaux dirigés contre les checkpoints immunologiques : de nouvelles approches d'immunothérapie en onco-hématologie. 2016 , 4, 5-12	2
1196	Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. 2016 , 213, 827-40	82
1195	Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. 2016 , 140, 249-54	69
1194	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. 2016 , 27, 1482-92	335
1193	The role of neoantigens in response to immune checkpoint blockade. 2016 , 28, 411-9	88
1192	The application of proteomics in different aspects of hepatocellular carcinoma research. 2016 , 145, 70-80	14
1191	Damage-associated molecular patterns in cancer: a double-edged sword. 2016 , 35, 5931-5941	217
1190	Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis. 2016 , 72, 650-658	17
1189	Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. 2016 , 5, e1075692	22
1188	The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. 2016 , 114, 1145-51	22
1187	Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas. 2016 , 294, 27-31	11
1186	Cancer cell-derived IL-1β induces CCL22 and the recruitment of regulatory T cells. 2016 , 5, e1175794	41
1185	Emerging nanotechnologies for cancer immunotherapy. 2016 , 241, 1116-26	20
1184	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. 2016 , 96, 805-29	43

1183	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. 2016 , 8, 583-600	52
1182	Recent developments in the use of immunotherapy in non-small cell lung cancer. 2016 , 10, 781-98	23
1181	Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. 2016 , 22, 679-84	445
1180	Immunomodulation of classical and non-classical HLA molecules by ionizing radiation. 2016 , 303, 16-23	8
1179	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. 2016 , 28, 373-82	108
1178	Implikationen der TCGA Netzwerkdaten für Zweit-Generations-Immuntherapiekonzepte auf Basis der PD-L1 und PD-1 Zielstrukturen. 2016 , 37, 150-154	
1177	Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis. 2016 , 1023-1024, 9-16	33
1176	Current Challenges in Cancer Treatment. 2016 , 38, 1551-66	318
1175	NLR5/MHC class I transactivator is a target for immune evasion in cancer. 2016 , 113, 5999-6004	130
1174	TG4010: a vaccine with a therapeutic role in cancer. 2016 , 8, 511-9	11
1173	Opioids and cancer: friend or foe?. 2016 , 10, 109-18	36
1172	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. 2016 , 76, 3496-506	27
1171	Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. 2016 , 127, 3350-9	27
1170	NETs in cancer. 2016 , 37, 14355-14361	37
1169	Novel targets and interaction partners of mutant p53 Gain-Of-Function. 2016 , 44, 460-6	36
1168	Progress and opportunities for immune therapeutics in osteosarcoma. 2016 , 8, 1233-44	28
1167	Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential. 2016 , 8, 1219-32	17
1166	Regulatory T Cells and Cancer: A Two-Sided Story. 2016 , 45, 797-812	30

1165	Radiotherapy: Changing the Game in Immunotherapy. 2016 , 2, 286-294	200
1164	Human biofield therapy does not affect tumor size but modulates immune responses in a mouse model for breast cancer. 2016 , 14, 389-99	4
1163	Emerging roles of p53 and other tumour-suppressor genes in immune regulation. 2016 , 16, 741-750	187
1162	Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them. 2016 , 9, 1007-1009	7
1161	Mouse models in oncoimmunology. 2016 , 16, 759-773	185
1160	The Relationship Between Dormant Cancer Cells and Their Microenvironment. 2016 , 132, 45-71	92
1159	The genomic landscape of breast cancer and its interaction with host immunity. 2016 , 29, 241-50	130
1158	Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. 2016 , 50, 205-207	41
1157	Étude des lymphocytes Th9 humains dans les cancers du sein. 2016 , 100, 181-182	
1156	EpsteinBarr Virus Infection and Lymphoproliferative Disorders After Transplantation. 2016 , 477-512	2
1155	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. 2016 , 34, 4102-4109	400
1154	Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy. 2016 , 10, 9227-9242	34
1153	CD4FOXP3 T regulatory cells decrease and CD3CD8 T cells recruitment in TILs from melanoma metastases after electrochemotherapy. 2016 , 33, 787-798	18
1152	The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. 2016 , 16, 903-10	5
1151	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. 2016 , 18, 59	28
1150	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. 2016 , 21, 910-21	42
1149	Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. 2016 , 5, 778-86	29
1148	The immune system and cancer evasion strategies: therapeutic concepts. 2016 , 279, 541-62	146

1147	Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity. 2016 , 24, 1444-55	17
1146	Association of the HLA-G 3'UTR polymorphisms with colorectal cancer in Italy: a first insight. 2016 , 43, 32-9	14
1145	Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells. 2016 , 76, 6017-6029	85
1144	The Tumor Microenvironment. 2016 ,	3
1143	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. 2016 , 1458, 159-77	5
1142	Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). 2016 , 21, 243-54	4
1141	Could zinc oxide tetrapod nanoparticles be used as an effective immunotherapy against HSV-2?. 2016 , 11, 2239-42	5
1140	The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma. 2016 , 5, e1218106	39
1139	Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic Immunity. 2016 , 9, 418-432	10
1138	Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. 2016 , 17, 174	942
1137	The epidemiology of metastases in neuroendocrine tumors. 2016 , 139, 2679-2686	132
1136	Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse. 2016 , 7, 10823	36
1135	Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer. 2016 , 17, 2234-2246	43
1134	Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. 2016 , 3, 16002	25
1133	Targeting the cancer epigenome for therapy. 2016 , 17, 630-41	649
1132	From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks. 2016 , 5, e1230579	4
1131	Immunotherapy for prostate cancer: False promises or true hope?. 2016 , 122, 3598-3607	19
1130	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. 2016 , 21, 1200-1211	164

1129	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. 2016 , 22, 4550-5	55
1128	Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome. 2016 , 23, 508-515	36
1127	The Wilms' Tumor (WT1) Gene. 2016 ,	
1126	Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. 2016 , 5, e1192740	11
1125	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. 2016 , 16, 1209-23	14
1124	Epithelial ovarian cancer inherent resistance: May the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role?. 2016 , 18, 57-58	43
1123	Ecr4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling. 2016 , 5, e1242547	12
1122	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. 2016 , 1, e000022	13
1121	One microenvironment does not fit all: heterogeneity beyond cancer cells. 2016 , 35, 601-629	41
1120	Interactions between immune challenges and cancer cells proliferation: timing does matter!. 2016 , 2016, 299-311	7
1119	Immune cell recruitment in teratomas is impaired by increased Wnt secretion. 2016 , 17, 607-615	16
1118	T Cells in Cancer: Beyond Classical Immunological Control. 2016 , 45, 721-728	2
1117	Dectin-1 predicts adverse postoperative prognosis of patients with clear cell renal cell carcinoma. 2016 , 6, 32657	5
1116	Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). 2016 , 18, 533-542	2
1115	Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy. 2016 , 23, 400-409	18
1114	Characterization of cytokinome landscape for clinical responses in human cancers. 2016 , 5, e1214789	19
1113	Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: A Meta-analysis. 2016 , 6, 33789	33
1112	The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort. 2016 , 6, 34823	45

1111	Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. 2016 , 7, 12499	484
1110	Patterns of metastasis in colon and rectal cancer. 2016 , 6, 29765	409
1109	A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma. 2016 , 6, 32259	9
1108	Prognostic value of platelet to lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. 2016 , 6, 35378	29
1107	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. 2016 , 6, 30093	155
1106	Significance of cancer-associated fibroblasts in head and neck squamous cell carcinoma. 2016 , 34, 211-219	
1105	Circulating Neutrophil MicroRNAs as Biomarkers for the Detection of Lung Cancer. 2016 , 8, 1-7	11
1104	GRIN3A and MAPT stimulate nerve overgrowth in macrodactyly. 2016 , 14, 5637-5643	3
1103	Age-Dependent Metastatic Spread and Survival: Cancer of Unknown Primary as a Model. 2016 , 6, 23725	9
1102	Large molecular systems landscape uncovers T cell trapping in human skin cancer. 2016 , 6, 19012	10
1101	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. 2016 , 10, 31-9	88
1100	Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational study-CAPITAL (Cohort and Practice for IBD total management in Kyoto-Shiga Links) study I. 2016 , 3, e000122	6
1099	Immunotherapy with radiotherapy in urological malignancies. 2016 , 26, 514-22	5
1098	Current Status of Immunotherapy Treatments for Pancreatic Cancer. 2016 , 50, 836-848	10
1097	Cancer immunotherapy: new applications in urologic oncology. 2016 , 26, 535-42	9
1096	Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. 2016 , 22, 267-73	8
1095	Mechanisms of Metastasis of Solid Organ Tumors in the Perioperative Period. 2016 , 54, 29-47	2
1094	Checkpoint inhibition in meningiomas. 2016 , 8, 721-31	18

1093	Progress in Cancer Immunotherapy. 2016 ,	5
1092	Harnessing the immune system in acute myeloid leukaemia. 2016 , 103, 62-77	61
1091	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. 2016 , 76, 4100-12	39
1090	Immunotherapy in Breast Cancer. 2016 , 39, 335-45	11
1089	Promoter methylation and mRNA expression of HLA-G in relation to HLA-G protein expression in colorectal cancer. 2016 , 77, 764-72	7
1088	CD169 identifies an activated CD8(+) T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients. 2016 , 5, e1177690	13
1087	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. 2016 , 48, 20-4	90
1086	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. 2016 , 17, 40	17
1085	Mathematical model of tumor-immune surveillance. 2016 , 404, 312-330	38
1084	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. 2016 , 44, 1255-69	554
1083	Mouse Models of Tumor Immunotherapy. 2016 , 130, 1-24	25
1082	Number of Intratumoral T Lymphocytes Is Associated With Lymph Node Size, Lymph Node Harvest, and Outcome in Node-Negative Colon Cancer. 2016 , 145, 826-36	22
1081	Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. 2016 , 108,	187
1080	Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. 2016 , 213, 1133-9	55
1079	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. 2016 , 11, 102-7	17
1078	FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). 2016 , 38, 3-15	203
1077	Genomic determinants of cancer immunotherapy. 2016 , 41, 32-38	20
1076	Functional Analysis of Histone Deacetylase 11 (HDAC11). 2016 , 1436, 147-65	7

1075	Histone Deacetylases. 2016,	1
1074	Adoptive Cellular Therapy (ACT) for Cancer Treatment. 2016, 909, 169-239	10
1073	A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. 2016, 5, e1189051	15
1072	Personalized immunotherapy in colorectal cancer. 2016, 1, 267-277	2
1071	Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. 2016, 18, 25	46
1070	T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. 2016, 34, 3787-3795	66
1069	Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. 2016, 5, e1153208	30
1068	TAM receptor tyrosine kinase function and the immunopathology of liver disease. 2016, 310, G899-905	16
1067	Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. 2016, 30, 1805-15	20
1066	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. 2016, 5, e1139275	17
1065	Extracellular 2'5'-oligoadenylate synthetase 2 mediates T-cell receptor CD3- ζ chain down-regulation via caspase-3 activation in oral cancer. 2016, 147, 251-64	17
1064	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. 2016, 166, 9-29	22
1063	Clinical Development of the E75 Vaccine in Breast Cancer. 2016, 11, 116-21	25
1062	Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. 2016, 142, 1775-80	11
1061	A fate worse than death: apoptosis as an oncogenic process. 2016, 16, 539-48	234
1060	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. 2016, 4, 3	146
1059	Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity. 2016, 196, 759-66	117
1058	CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. 2016, 5, e1061175	22

1057	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. 2016 , 12, 551-64	7
1056	Yeast-Derived Particulate β -Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer. 2016 , 196, 2167-80	65
1055	Acquired resistance to immunotherapy and future challenges. 2016 , 16, 121-6	260
1054	Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. 2016 , 6, 4	9
1053	Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells. 2016 , 164, 365-77	188
1052	Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions. 2016 , 149, 1494-500	19
1051	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. 2016 , 22, 3057-66	154
1050	Immune Therapy. 2016 , 893, 59-90	1
1049	Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. 2016 , 1863, 471-482	67
1048	Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma. 2016 , 34, e110-6	13
1047	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. 2016 , 2, 46-54	527
1046	Myeloid-Derived Suppressor Cells: Possible Link Between Chronic Obstructive Pulmonary Disease and Lung Cancer. 2016 , 52, 29-35	1
1045	Lung Cancer and Personalized Medicine. 2016 ,	13
1044	Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. 2016 , 94, 571-9	123
1043	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. 2016 , 13, 228-41	429
1042	IL17A-Mediated Endothelial Breach Promotes Metastasis Formation. 2016 , 4, 26-32	26
1041	Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. 2016 , 65, 1-11	27
1040	Cancer Immunosurveillance Caught in the Act. 2016 , 44, 525-526	4

1039	HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases. 2016 , 77, 773-9	28
1038	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. 2016 , 12, 864-75	75
1037	Combining Epigenetic and Immunotherapy to Combat Cancer. 2016 , 76, 1683-9	190
1036	Update on Metastatic Uveal Melanoma: Progress and Challenges. 2016 , 30, 161-72	11
1035	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. 2016 , 21, 283-91	35
1034	Principles of immunotherapy. 2016 , 134, 163-81	7
1033	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. 2016 , 28, 383-91	146
1032	Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. 2016 , 21, 608-17	60
1031	Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. 2016 , 14, 28-37	
1030	Immunotherapy of melanoma: efficacy and mode of action. 2016 , 14, 28-37	12
1029	Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets. 2016 , 31, 1393-404	19
1028	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. 2016 , 130, 25-74	119
1027	Inflammatory Cells in Tumor Microenvironment. 2016 , 27-50	
1026	Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses. 2016 , 86, 83-91	54
1025	Immunotherapy for small-cell lung cancer: emerging evidence. 2016 , 12, 931-43	37
1024	The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation. 2016 , 1865, 168-75	21
1023	New Strategies in Breast Cancer: Immunotherapy. 2016 , 22, 2105-10	90
1022	Biomaterials for enhancing anti-cancer immunity. 2016 , 40, 1-8	94

1021	Leukocyte populations and IL-6 in the tumor microenvironment of an orthotopic colorectal cancer model. 2016 , 48, 334-41	13
1020	The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. 2016 , 17, 161-8	13
1019	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. 2016 , 44, 343-54	518
1018	Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers. 2016 , 30, 1344-54	42
1017	Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. 2016 , 5, e1111505	20
1016	The Role of Microenvironment in the Control of Tumor Angiogenesis. 2016 ,	3
1015	The Role of the Immune System in Ovarian Cancer and Implications on Therapy. 2016 , 12, 681-95	5
1014	CD47: a potential immunotherapy target for eliminating cancer cells. 2016 , 18, 1051-1055	32
1013	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. 2016 , 7, 10346	142
1012	The properties of the anti-tumor model with coupling non-Gaussian noise and Gaussian colored noise. 2016 , 449, 43-52	8
1011	The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. 2016 , 11, 789-800	229
1010	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. 2016 , 140, 326-31	99
1009	Lymphocyte-to-monocyte ratios predict gastric cancer surgical outcomes. 2016 , 202, 284-90	40
1008	Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients. 2016 , 15, 477-83	130
1007	CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma. 2016 , 5, e1151594	45
1006	STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. 2016 , 76, 2076-81	152
1005	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. 2016 , 21, 462-73	190
1004	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. 2016 , 57, 91-103	95

1003	The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. 2016 , 8, 327ra26	291
1002	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. 2016 , 468, 511-25	172
1001	Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?. 2016 , 5, e1112942	16
1000	Coinhibitory Pathways in Immunotherapy for Cancer. 2016 , 34, 539-73	507
999	Immunotherapy of Cancer. 2016 ,	2
998	Autoantigens as Partners in Initiation and Propagation of Autoimmune Rheumatic Diseases. 2016 , 34, 395-420	26
997	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. 2016 , 13, 273-90	640
996	The interplay between the microbiome and the adaptive immune response in cancer development. 2016 , 9, 594-605	39
995	Personalized Peptide Vaccine. 2016 , 143-158	
994	Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy. 2016 , 349-358	
993	Asymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy. 2016 , 73, 867-83	5
992	Radiotherapy in patients with connective tissue diseases. 2016 , 17, e109-e117	31
991	Therapy-induced microenvironmental changes in cancer. 2016 , 94, 497-508	13
990	PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer. 2016 , 11, 62-71	110
989	Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and Nkp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia. 2016 , 47, 55-64	18
988	Prospect and progress of personalized peptide vaccinations for advanced cancers. 2016 , 16, 689-98	10
987	Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. 2016 , 8, 415-28	50
986	Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. 2016 , 15, 235-47	358

985	Vaccines for established cancer: overcoming the challenges posed by immune evasion. 2016 , 16, 219-33	449
984	MYC regulates the antitumor immune response through CD47 and PD-L1. <i>Science</i> , 2016 , 352, 227-31	333 651
983	Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. 2016 , 59, 340-8	43
982	Advances in Therapeutic Cancer Vaccines. 2016 , 130, 191-249	71
981	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. 2016 , 5, e1149674	41
980	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. 2016 , 8, 4-31	36
979	Pi (Spleen)-deficiency syndrome in tumor microenvironment is the pivotal pathogenesis of colorectal cancer immune escape. 2016 , 22, 789-94	11
978	O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. 2016 , 108, 564-576	27
977	Myeloid-Derived Suppressor Cells: Possible Link Between Chronic Obstructive Pulmonary Disease and Lung Cancer. 2016 , 52, 29-35	5
976	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. 2016 , 16, 56-66	266
975	NK cells and cancer: you can teach innate cells new tricks. 2016 , 16, 7-19	622
974	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN γ That Induce PD-L1 Expression in Head and Neck Cancer. 2016 , 76, 1031-43	193
973	The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis. 2016 , 22, 3268-80	10
972	Immunosuppressive cells in tumor immune escape and metastasis. 2016 , 94, 509-22	168
971	Systems Immunology. 2016 , 3-44	
970	Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. 2016 , 22, 2237-49	60
969	Identification of melanoma cells and lymphocyte subpopulations in lymph node metastases by FTIR imaging histopathology. 2016 , 1862, 202-12	21
968	Development of a squamous cell carcinoma mouse model for immunotoxicity testing. 2016 , 13, 226-34	6

967	Senescence and cancer: An evolving inflammatory paradox. 2016 , 1865, 14-22	25
966	An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. 2016 , 76, 73-82	206
965	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. 2016 , 22, 337-45	43
964	Novel avenues in immunotherapies for colorectal cancer. 2016 , 10, 465-80	8
963	The re-polarisation of M2 and M1 macrophages and its role on cancer outcomes. 2016 , 390, 23-39	39
962	Combination cancer immunotherapies tailored to the tumour microenvironment. 2016 , 13, 143-58	561
961	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. 2016 , 27, 249-56	96
960	Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. 2016 , 16, 13-20	51
959	Novel Treatments in Development for Melanoma. 2016 , 167, 371-416	10
958	Immunologic approaches to cancer prevention-current status, challenges, and future perspectives. 2016 , 43, 161-172	28
957	The role of microenvironment and immunity in drug response in leukemia. 2016 , 1863, 414-426	51
956	Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer. 2016 , 5, e1081328	20
955	Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies. 2016 , 65, 101-9	35
954	Cancer Neoantigens and Applications for Immunotherapy. 2016 , 22, 807-12	146
953	Immune checkpoint inhibitors: a new frontier in bladder cancer. 2016 , 34, 49-55	11
952	Collective learning modeling based on the kinetic theory of active particles. 2016 , 16, 123-39	69
951	Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients. 2016 , 29, 122-30	22
950	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. 2016 , 5, e1088631	81

949	Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. 2016 , 24, 166-74	133
948	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. 2016 , 35, 3209-16	160
947	Epidemiology, Risk Factors, and Survival in CUP: Pointers to Disease Mechanisms. 2016 , 5-25	
946	Key mechanisms involved in ionizing radiation-induced systemic effects. A current review. 2016 , 5, 12-33	45
945	The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. 2016 , 34, 181-7	55
944	CAR-modified T-cell therapy for cancer: an updated review. 2016 , 44, 1339-49	36
943	The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells. 2016 , 35, 269-78	27
942	Advances in personalized cancer immunotherapy. 2017 , 24, 16-24	55
941	Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. 2017 , 89, 209-218	29
940	Tricking the balance: NK cells in anti-cancer immunity. 2017 , 222, 11-20	111
939	The innate immune signaling in cancer and cardiometabolic diseases: Friends or foes?. 2017 , 387, 46-60	16
938	Pretreatment predictive value of blood neutrophil/lymphocyte ratio in R0 gastric cancer resectability. 2017 , 40, 1-9	6
937	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. 2017 , 14, 115-128	62
936	Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. 2017 , 6, e1163456	22
935	Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma. 2017 , 15, 315-327	10
934	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. 2017 , 7,	16
933	Interrogating open issues in cancer precision medicine with patient-derived xenografts. 2017 , 17, 254-268	369
932	Pretreatment predictive value of blood neutrophil/lymphocyte ratio in R0 gastric cancer resectability. 2017 , 40, 1-9	

931	Spatial avascular growth of tumor in a homogeneous environment. 2017 , 416, 99-112	4
930	[Evaluation of the immune infiltrate in breast cancer]. 2017 , 104, 52-68	0
929	Ovarian cancer and the immune system. 2017 , 19, 57-58	12
928	Management of Prostate Cancer. 2017 ,	3
927	Microbes and Cancer. 2017 , 35, 199-228	127
926	Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGF β in Human Gastric Cancer. 2017 , 5, 248-256	83
925	Experimental animal modeling for immuno-oncology. 2017 , 173, 34-46	25
924	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. 2017 , 5, 106-117	162
923	Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. 2017 , 69, 687-699	78
922	Determinants of metastatic competency in colorectal cancer. 2017 , 11, 97-119	101
921	Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. 2017 , 331, 1-53	30
920	Radiotherapy and immunotherapy: a beneficial liaison?. 2017 , 14, 365-379	504
919	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. 2017 , 10, 34	63
918	[The "immune checkpoints", how does it work]. 2017 , 37, 18-28	2
917	Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap. 2017 , 3, 149-160	63
916	Emerging role of checkpoint blockade therapy in lymphoma. 2017 , 8, 81-90	20
915	State of the art in anti-cancer mAbs. 2017 , 24, 15	53
914	The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1. 2017 , 198, 2989-2999	29

913	MYC: Master Regulator of Immune Privilege. 2017 , 38, 298-305	49
912	Targeting neoantigens to augment antitumour immunity. 2017 , 17, 209-222	449
911	Potential immunotherapy targets in recurrent cervical cancer. 2017 , 145, 462-468	14
910	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. 2017 , 23, 3510-3519	86
909	NLR5/CITA: A Key Player in Cancer Immune Surveillance. 2017 , 3, 28-38	36
908	The role of lymph node size and FOXP3+ regulatory T cells in node-negative colon cancer. 2017 , 70, 443-447	9
907	[Immune system and tumors]. 2017 , 37, 11-17	4
906	[Focus on the Immunoscore and its potential clinical implications]. 2017 , 37, 29-38	8
905	Autoantibodies: Opportunities for Early Cancer Detection. 2017 , 3, 198-213	66
904	T Cell-Associated Immunotherapy for Hepatocellular Carcinoma. 2017 , 41, 609-622	25
903	Towards a better cancer precision medicine: systems biology meets immunotherapy. 2017 , 2, 67-73	5
902	It's a long way to the top (if you want to personalize immunotherapy). 2017 , 5, 6	1
901	Phenotype and function of tumor-associated neutrophils and their subsets in early-stage human lung cancer. 2017 , 66, 997-1006	34
900	IFN- γ s required for cytotoxic T cell-dependent cancer genome immunoeediting. 2017 , 8, 14607	80
899	A comprehensive review of immunotherapies in prostate cancer. 2017 , 113, 292-303	43
898	Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. 2017 , 8, 14447	12
897	Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. 2017 , 15, 5	23
896	Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. 2017 , 17, 91	36

895	HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. 2017 , 6, e1171447	43
894	New checkpoints in cancer immunotherapy. 2017 , 276, 52-65	91
893	Immunoregulatory functions of VISTA. 2017 , 276, 66-79	104
892	Hypermutated Colorectal Cancer and Neoantigen Load. 2017 , 187-215	2
891	Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development. 2017 , 8, 14677	96
890	Debugging the Black Box. 2017 , 7, 250-251	
889	Extracellular vesicles in lung cancer-From bench to bedside. 2017 , 67, 39-47	38
888	Second- and third-generation drugs for immuno-oncology treatment-The more the better?. 2017 , 74, 55-72	155
887	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. 2017 , 8, 14340	80
886	Cancer treatment and the KIR-HLA system: an overview. 2017 , 17, 419-429	17
885	Radiotherapy in the age of cancer immunology: Current concepts and future developments. 2017 , 112, 1-10	16
884	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. 2017 , 6, e1314424	69
883	Tumor-associated myeloid cells as guiding forces of cancer cell stemness. 2017 , 66, 1025-1036	37
882	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. 2017 , 20, 205-215	52
881	Prediction of optimal gene functions for osteosarcoma using network-based- guilt by association method based on gene oncology and microarray profile. 2017 , 7, 18-22	5
880	Advances in Radiation Oncology. 2017 ,	5
879	Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay. 2017 , 35, 377-385	2
878	PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system. 2017 , 6, e1315488	48

877	Role of sialyl 6-sulfo Lewis X in antitumor immunity against oral squamous cell carcinoma. 2017 , 46, 759-765	1
876	The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data. 2017 , 34, 101	80
875	Tuning cancer fate: the unremitting role of host immunity. 2017 , 7,	25
874	Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. 2017 , 28, 1658-1666	17
873	Identification of Immunogenic Epitopes by MS/MS. 2017 , 23, 102-107	17
872	Causality, Information, and Biological Computation: An Algorithmic Software Approach to Life, Disease, and the Immune System. 244-280	4
871	Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy. 2017 , 23, 144-148	7
870	The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with hepatocellular carcinoma: A meta-analysis. 2017 , 7, 46601	31
869	Cancer Stem Cells and Tumor Microenvironment in Radiotherapy. 2017 , 191-221	
868	IL-18 receptor marks functional CD8 T cells in non-small cell lung cancer. 2017 , 6, e1328337	15
867	[Cancer, radiotherapy and immune system]. 2017 , 21, 307-315	8
866	Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase II β in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy. 2017 , 62, 246-255	6
865	Extended Abstracts Fall 2015. 2017 ,	
864	Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. 2017 , 18, 682-691.e5	57
863	Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN- γ -induced immunologic dormancy of tumor-repopulating cells. 2017 , 8, 15207	90
862	In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. 2017 , 9,	331
861	Modular lentiviral vector system for chimeric antigen receptor design optimization. 2017 , 43, 107-114	3
860	Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. 2017 , 56, 651-659	30

859	An Immune Atlas of Clear Cell Renal Cell Carcinoma. 2017 , 169, 736-749.e18	501
858	Pancreatic Cancer. 2017 ,	1
857	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. 2017 , 40, 132-139	4
856	The prognostic value of B7-H6 protein expression in human oral squamous cell carcinoma. 2017 , 46, 766-772	15
855	The Immunobiology of Cancer: From Tumor Escape to Cancer Immunoediting Towards Immunotherapy in Gynecologic Oncology. 2017 , 193-204	1
854	Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia. 2017 , 105, 453-464	13
853	Relationship of the Breast Ductal Carcinoma Immune Microenvironment with Clinicopathological and Genetic Features. 2017 , 23, 5210-5217	41
852	High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma: A cohort study. 2017 , 96, e6472	27
851	Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. 2017 , 38, 223-232	23
850	Cancer stem cells: at the forefront of personalized medicine and immunotherapy. 2017 , 35, 1-11	37
849	Hallmarks of response to immune checkpoint blockade. 2017 , 117, 1-7	138
848	Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. 2017 , 17, 471-478	23
847	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. 2017 , 6, e1339856	6
846	The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. 2017 , 6, e1338996	15
845	The multifaceted roles of inflammasome proteins in cancer. 2017 , 29, 35-40	24
844	Intestine-Specific Homeobox Gene Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression. 2017 , 77, 4065-4077	19
843	DNA Damage and Repair Biomarkers of Immunotherapy Response. 2017 , 7, 675-693	331
842	Novel "Elements" of Immune Suppression within the Tumor Microenvironment. 2017 , 5, 426-433	43

841	CD45RAFoxp3 regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma. 2017 , 66, 1275-1285	29
840	Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth. 2017 , 11, 5417-5429	96
839	IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. 2017 , 8, 15776	86
838	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. 2017 , 9,	167
837	Cancer cell and macrophage cross-talk in the tumor microenvironment. 2017 , 35, 12-19	122
836	Unravelling the biology of SCLC: implications for therapy. 2017 , 14, 549-561	209
835	Nanomaterial-Enabled Cancer Therapy. 2017 , 25, 1501-1513	85
834	Immunotherapeutic properties of chemotherapy. 2017 , 35, 83-88	19
833	Personalized peptide vaccines and their relation to other therapies in urological cancer. 2017 , 14, 501-510	20
832	Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. 2017 , 108, 1022-1031	66
831	Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. 2017 , 77, 3894-3907	113
830	A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma. 2017 , 143, 2077-2086	52
829	An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. 2017 , 77, 4158-4170	50
828	Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents. 2017 , 9, 149-168	59
827	[Brain tumor immunotherapy: Illusion or hope?]. 2017 , 104, 476-484	
826	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. 2017 , 7, 630-651	34
825	A key to the backdoor into the castle: The clinical ramifications of immunoediting driven by antigenic competition. 2017 , 13, 1579-1585	
824	Mechanisms governing metastatic dormancy in breast cancer. 2017 , 44, 72-82	41

823	Cancer immunotherapies targeting the PD-1 signaling pathway. 2017 , 24, 26	332
822	Human papilloma virus load and PD-1/PD-L1, CD8 and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. 2017 , 6, e1288331	53
821	Cytokine-induced senescence for cancer surveillance. 2017 , 36, 357-365	7
820	Molecular Oncology: Underlying Mechanisms and Translational Advancements. 2017 ,	1
819	Pelvic radiotherapy in the setting of rheumatoid arthritis: Refining the paradigm. 2017 , 21, 109-113	2
818	Cancer immunotherapy: how low-level ionizing radiation can play a key role. 2017 , 66, 819-832	37
817	Obstacles Posed by the Tumor Microenvironment to T'cell Activity: A Case for Synergistic Therapies. 2017 , 31, 311-325	326
816	Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. 2017 , 6, e1267891	48
815	Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. 2017 , 7,	32
814	Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase. 2017 , 23, 2928-2933	43
813	Mechanisms of Resistance to Immune Checkpoint Antibodies. 2018 , 249, 109-128	21
812	Role of AHR and HIF-1 β in Glioblastoma Metabolism. 2017 , 28, 428-436	58
811	Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. 2017 , 17, 735-746	36
810	Modeling cancer evolution: evolutionary escape under immune system control. 2017 , 811, 012004	10
809	PTEN at the interface of immune tolerance and tumor suppression. 2017 , 12, 163-174	16
808	Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. 2017 , 68, 36-43	46
807	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. 2017 , 76, 152-166	62
806	Immune targets and neoantigens for cancer immunotherapy and precision medicine. 2017 , 27, 11-37	139

805	TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?.	2017 , 11, 354-363	39
804	Immunotherapy for Gastrointestinal Cancer.	2017 ,	0
803	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.	2017 , 6, e1260214	5
802	The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.	2017 , 12, 153-186	261
801	Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways.	2017 , 95, 99-109	46
800	Whole-exome sequencing predicted cancer epitope trees of 23 early cervical cancers in Chinese women.	2017 , 6, 207-219	7
799	The Biology of Head and Neck Cancer.	2017 , 51-66	
798	Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.	2017 , 126, 983-996	24
797	Immune Metabolism in Health and Tumor.	2017 ,	3
796	Wandering pathways in the regulation of innate immunity and inflammation.	2017 , 85, 1-5	20
795	Further insight into AE37 peptide vaccination in prostate cancer.	2017 , 3, FSO192	
794	Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer.	2017 , 322, 26-33	8
793	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials.	2017 , 2, e000236	19
792	Immunotherapy of Hepatocellular Carcinoma.	2017 ,	
791	Immune checkpoint inhibitors in renal cell carcinoma.	2017 , 131, 2627-2642	38
790	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.	2017 , 6, e1386829	143
789	Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.	2017 , 5, 992-1004	99
788	GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.	2017 , 6, e1353860	18

787	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. 2017 , 119, 30-39	29
786	Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). 2017 , 51, 1357-1369	196
785	Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. 2017 , 280, 126-148	178
784	The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. 2017 , 60, 1058-1064	12
783	Nanotechnology-Based Immunotherapeutic Strategies for the Treatment of Cancer. 2017 , 83-115	1
782	Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. 2017 , 280, 249-279	110
781	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. 2017 , 280, 165-174	52
780	VSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients. 2015 , 7, 1172-80	14
779	Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. 2015 , 88, 389-95	3
778	Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. 2015 , 29, 908-20, 922	46
777	Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. 2016 , 30, 59-66, 69	14
776	Nanoparticles for Effective Combination Therapy of Cancer. 2016 , 1,	6
775	CCR6 B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis. 2017 , 7, 1151-1163	10
774	Interrogating Patient-level Genomics and Mouse Phenomics towards Understanding Cytokines in Colorectal Cancer Metastasis. 2017 , 2017, 227-236	
773	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. 2016 , 7, 498-509	6
772	Blocking LLT1 (CLEC2D, OCIL)-NKR1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. 2018 , 8, 1050-1063	16
771	Promising new treatments for pancreatic cancer in the era of targeted and immune therapies. 2019 , 9, 1871-1888	10
770	Infiltrating CD4/CD8 high T cells shows good prognostic impact in pancreatic cancer. 2017 , 10, 8820-8828	6

769	[PD-1/PD-L1 expression and its implications in patients with chronic lymphocytic leukemia]. 2017 , 38, 198-203	1
768	COVID-19 Pandemic and the New State of Oncology Practice: An Editorial. 2020 , 8, 311-312	1
767	Attitudinal, regional and sex related vulnerabilities to COVID-19: Considerations for early flattening of curve in Nigeria. 2020 , 34, 61	1
766	The emerging prospects of circular RNA in tumor immunity. 2020 , 8, 1091	3
765	Current concept for tertiary lymphoid structures in urothelial carcinoma of the bladder: a literature review and our experience. 2020 , 9, 64-72	0
764	The role of an immune signature for prognosis and immunotherapy response in endometrial cancer. 2021 , 13, 532-548	4
763	PD-1, TIM-3, and LAG-3 Expression in T Cells in a Patient with Recurrent Ossifying Fibroma: A Case Report. 2020 , 9, 307-312	
762	Characterization of Immune-Related Long Non-coding RNAs to Construct a Novel Signature and Predict the Prognosis and Immune Landscape of Soft Tissue Sarcoma. 2021 , 9, 709241	
761	Postoperative psychological stress and expression of stress-related factors HSP70 and IFN- γ in patients with early lung cancer. 2020 ,	1
760	Xenograft cancer vaccines prepared from immunodeficient mice increase tumor antigen diversity and host T cell efficiency against colorectal cancers. 2021 , 526, 66-75	0
759	The Growing Relevance of Immunoregulation in Pediatric Brain Tumors. 2021 , 13,	2
758	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. 2021 , 12, 710943	1
757	Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer. 2021 , 12, 747780	1
756	Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. 2021 , 13,	5
755	Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. 2021 ,	56
754	Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. 2021 ,	5
753	Dual Targeting of Cancer Cells and MMPs with Self-Assembly Hybrid Nanoparticles for Combination Therapy in Combating Cancer.. 2021 , 13,	2
752	Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma. 2021 , 8, 755657	0

751	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. 2021 , 9,	2
750	Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. 2021 , 9,	1
749	Antimetastatic defense by CD8 T cells. 2021 ,	2
748	Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma.. 2021 , 11,	1
747	Identification and Characterization of Antigen-Specific CD8 T Cells Using Surface-Trapped TNF- β and Single-Cell Sequencing. 2021 ,	0
746	Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study. 2021 , 1	0
745	The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer. 2021 , 12, 784823	2
744	Computational cancer neoantigen prediction: current status and recent advances. 2021 , 100052	3
743	The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response. 2021 , 21, 3313-3331	3
742	Autophagy: A promising target for triple negative breast cancers. 2021 , 175, 106006	1
741	Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. 2022 , 23, 25	0
740	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. 2021 , 6, eabc6424	6
739	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. 2021 , 13,	0
738	Augmentation of antitumor function of tumor-infiltrating lymphocytes against triple-negative breast cancer by PD-1 blockade. 2021 ,	0
737	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. 2021 , 7, 150	17
736	Impact of immune cells on the hallmarks of cancer: A literature review. 2021 , 168, 103541	3
735	KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?. 2021 , 16, 1979-1983	0
734	Transcutaneous Vagal Nerve Stimulation Alone or in Combination With Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes But Fails to Suppress Tumor Growth.. 2021 , 12, 772555	

733	The Ratio of Cytotoxic Lymphocytes to M2-Like Macrophages is Prognostic in Immunogenic Tumors and Predicts Immunotherapy Response.	
732	Landscape of Immunotherapy in Genitourinary Malignancies.. 2021 , 1342, 143-192	0
731	Immune Landscape Refines the Classification of Colorectal Cancer With Heterogeneous Prognosis, Tumor Microenvironment and Distinct Sensitivity to Frontline Therapies.. 2021 , 9, 784199	3
730	Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.. 2022 ,	2
729	Identification of m6A-Associated Gene DST as a Prognostic and Immune-Associated Biomarker in Breast Cancer Patients.. 2022 , 15, 523-534	1
728	Enhancing the HSV-1-mediated antitumor immune response by suppressing Bach1.. 2022 ,	
727	The ALDH Family Contributes to Immunocyte Infiltration, Proliferation and Epithelial-Mesenchymal Transformation in Glioma.. 2021 , 12, 756606	4
726	Basics of Immunity. 2022 , 13-25	
725	Nanotechnology-Based Approaches to Promote Lymph Node Targeted Delivery of Cancer Vaccines.. 2022 ,	1
724	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.. 2021 , 146, 112516	7
723	Polymersomes as a potential platform for cancer immunotherapy. 2022 , 13, 100203	2
722	Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors.. 2022 , 24, 194-204	1
721	A critical role for B cells in cancer immune surveillance.	
720	The emerging prospects of circular RNA in tumor immunity. 2020 , 8, 1091-1091	3
719	Prognostic value of baseline white blood cell count and neutrophil/lymphocyte ratio in carcinoma cervix. 2021 , 1, 8	
718	Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited irAEs.. 2022 ,	2
717	Gene essentiality for tumour growth influences neoantigen-directed immunoediting.. 2022 , 12, e714	
716	Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.. 2022 , 13, 807271	2

715	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.. 2022 , 1	0
714	Tumor-endogenous PD-1 promotes cell proliferation and predicts poor survival in non-small cell lung cancer.. 2022 , 11, 3-13	0
713	Electrolyte and Acid-Base Disorders associated with Cancer Immunotherapy.. 2022 ,	1
712	The effect of performance score, prognostic nutritional index, serum neutrophil-to-lymphocyte ratio, and thrombocyte-to-lymphocyte ratio on prognosis in non-small cell lung cancer.	
711	A Prognostic Nomogram for Hepatocellular Carcinoma Based on Wound Healing and Immune Checkpoint Genes. 2022 , 10, 000-000	
710	Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity.. 2022 , 14,	1
709	Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct. 2022 , 11,	2
708	Paradoxical role of interleukin-33/suppressor of tumorigenicity 2 in colorectal carcinogenesis: Progress and therapeutic potential.. 2022 , 10, 23-34	
707	Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions.. 2022 , 2, 100153	0
706	Breast Cancer Vaccines: Disappointing or Promising?. 2022 , 13, 828386	3
705	CD74 and HLA-DRA in Cervical Carcinogenesis: Potential Targets for Antitumour Therapy.. 2022 , 58,	1
704	Comparison of the uptake of untargeted and targeted immunostimulatory nanoparticles by immune cells in the microenvironment of metastatic breast cancer. 2021 ,	2
703	The mechanism underlying arsenic-induced PD-L1 upregulation in BEAS-2B cells.. 2021 , 115845	0
702	Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight.. 2022 , 14,	1
701	Effects of Propofol Sevoflurane on Postoperative Breast Cancer Prognosis: A Narrative Review.. 2021 , 11, 793093	1
700	Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections.. 2022 , 10, 856-869	0
699	Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing.. 2022 , 11,	0
698	The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.. 2021 , 12, 802049	0

697	Exosomes in cancer immunoediting and immunotherapy.. 2022 , 17, 193-205	0
696	The effect of performance score, prognostic nutritional index, serum neutrophil-to-lymphocyte ratio, and thrombocyte-to-lymphocyte ratio on prognosis in non-small cell lung cancer. 94-99	
695	Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers.. 2022 , 14, 19-37	0
694	Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma.. 2021 , 12, 703821	0
693	Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment.. 2021 , 12, 832942	3
692	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.. 2021 , 12, 799455	7
691	Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma.. 2022 ,	1
690	Keep a Little Fire Burning-The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity.. 2022 , 23,	
689	Targeting FoxP3 gene to check out the impairment of tolerance in breast cancer patients. 2022 , 34, 101864	0
688	Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report.. 2022 , 14, e21770	0
687	SAA induces suppressive neutrophils via the TLR2-mediated signaling pathway to promote progression of breast cancer.. 2022 ,	1
686	Deciphering the Immune-Tumor Interplay During Early-Stage Lung Cancer Development Single-Cell Technology.. 2021 , 11, 716042	0
685	Current global trends in the development of CAR-T therapy. 2022 , 11, 1-9	
684	Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study.. 2022 , 1-9	1
683	Prognostic impact of count of extratumoral lymphatic permeation in lung adenocarcinoma and its relation to the immune microenvironment.. 2022 ,	1
682	Cancer Occurrence as the Upcoming Complications of COVID-19.. 2021 , 8, 813175	2
681	The initial expression alterations occurring to transcription factors during the formation of breast cancer: Evidence from bioinformatics.. 2022 ,	1
680	Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.. 2022 ,	1

- 679 The role of microbiota and immune system crosstalk in cancer development and therapy.. **2022,**
- 678 In silico view of MTA1 biochemical signatures in breast malignancy for improvement in immunosurveillance. **2022, 34, 101843**
- 677 Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures.. **2022, 13, 805184** 0
- 676 HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.. **2022,** 22
- 675 Targeting NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating anti-tumor immunity cycle.. **2022,** 0
- 674 Inflammatory and immune effects on tumor progression.. **2021,**
- 673 PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.. **2022, 38, 110331** 3
- 672 Immune modulating nanoparticles depleting tumor-associated macrophages to enhance immune checkpoint blockade therapy. **2022, 435, 134779** 1
- 671 COVID-19 in cancer patients.. **2022,** 3
- 670 Arsenic Trioxide Cooperate Cryptotanshinone Exerts Antitumor Effect by Medicating Macrophage Polarization through Glycolysis.. **2022, 2022, 2619781** 0
- 669 Post-transplant malignancies show reduced T-cell abundance and tertiary lymphoid structures as correlates of impaired cancer immunosurveillance.. **2022,** 1
- 668 Extrachromosomal DNA is associated with decreased immune cell infiltration and antigen presentation, represents a potential cancer immune evasion mechanism.
- 667 N6-Methyladenosine Methylation Regulator RBM15 is a Potential Prognostic Biomarker and Promotes Cell Proliferation in Pancreatic Adenocarcinoma.. **2022, 9, 842833** 2
- 666 Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer.. **2022, 16, 74**
- 665 C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.. **2022, 13, 808101** 2
- 664 Current Therapy and Development of Therapeutic Agents for Lung Cancer. **2022, 100015** 1
- 663 Senescence and the tumor-immune landscape: Implications for cancer immunotherapy.. **2022,** 2
- 662 Regulatory landscape in the approval of cancer vaccine. **2022, 325-348**

- 661 Complex dynamic behaviors of a tumor-immune system with two delays in tumor actions. **2022**,
- 660 Research progress in immunotherapy of NSCLC with EGFR sensitive mutations.. **2022**,
- 659 Environmental Conditions in Early Life, Host Defenses, and Disease in Late Life. **2022**, 127-160
- 658 Supramolecular biomaterials for enhanced cancer immunotherapy.. **2022**, 1
- 657 Natural killer cell-based strategies for immunotherapy of cancer.. **2022**, 129, 91-133 1
- 656 Effects of Low Dose Splenic Region Irradiation and Low Dose Total Body Irradiation on T Cell Immune Function in Mice. **2022**, 12, 2519-2526
- 655 Advanced Nanovaccines Based on Engineering Nanomaterials for Accurately Enhanced Cancer Immunotherapy.
- 654 Melanoma therapeutics: a literature review.. **2022**, 1-21 1
- 653 Cancer immunotherapy. **2022**, 295-311
- 652 Sialic Acid-Binding Ig-Like Lectins (Siglecs). **2022**, 311-496
- 651 Normality sensing licenses local T cells for innate-like tissue surveillance.. **2022**, 3
- 650 Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker.. **2022**, 12, 795277 0
- 649 The Role of Extracellular Matrix Proteins in Breast Cancer.. **2022**, 11, 3
- 648 Insights into the Association Between QSER1 and M2 Macrophages and Remarkable Malignancy Characteristics in Hepatocellular Carcinoma.. **2022**, 15, 1765-1775
- 647 Expression of CD28 in Hepatocellular Carcinoma and Its Prognostic Value. **2022**, 21,
- 646 Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.. **2022**, 15, 17 2
- 645 Machine learning predicts cancer subtypes and progression from blood immune signatures.. **2022**, 17, e0264631 0
- 644 Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.. **2022**, 16, 363-374 3

643	Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.. 2022 , 10,	1
642	Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer.. 2022 , 8, 26	0
641	Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers.. 2022 , 14,	4
640	The Unfolded Protein Response at the Tumor-Immune Interface.. 2022 , 13, 823157	1
639	Decoding the influence of the immune system and immunotherapy targets on carcinomas: A hidden prism in oral cancer therapy.. 2022 , 101353	1
638	A multispecific anti-CD40 DARPin \square construct induces tumor-selective CD40 activation and tumor regression.. 2022 ,	0
637	Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.. 2022 , 12, 788113	1
636	lLnc: Prioritizing Long Non-coding RNAs for Pan-cancer Analysis of Immune Cell Infiltration.	
635	Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.. 2022 ,	1
634	ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas.. 2022 , 12, 844144	1
633	Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma.. 2022 , 12, 827051	1
632	Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma.. 2022 , 13, 847263	
631	Neutrophil to lymphocyte ratio based perioperative prediction of prognosis model on early mortality after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.. 2022 ,	0
630	Basic cancer immunology for radiation oncologists.. 2022 ,	1
629	In Vivo Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes.. 2022 , 2, e377	0
628	Extrachromosomal DNA formation enables tumor immune escape potentially through regulating antigen presentation gene expression.. 2022 , 12, 3590	1
627	T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.. 2022 , 10,	0
626	Tolerogenic IDO1CD83 Langerhans Cells in Sentinel Lymph Nodes of Patients with Melanoma.. 2022 , 23,	2

625	Prognosticators and Prognostic Nomograms for Leiomyosarcoma Patients With Metastasis.. 2022 , 12, 840962	0
624	Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy.. 2022 ,	
623	Loss of HLA-class-I expression in non-small-cell lung cancer: Association with prognosis and anaerobic metabolism.. 2022 , 373, 104495	0
622	Tumor immunology CRISPR screening: present, past, and future.. 2021 ,	1
621	Roles of RNA-binding proteins in immune diseases and cancer.. 2022 ,	0
620	Evaluation of Immune Infiltration Based on Image Plus Helps Predict the Prognosis of Stage III Gastric Cancer Patients with Significantly Different Outcomes in Northeastern China.. 2022 , 2022, 2893336	2
619	Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future.. 2022 , 14,	0
618	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. 2022 , 22, 40-50	
617	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.. 2022 , e2200027	3
616	Tumor cell intrinsic and extrinsic features predict prognosis in estrogen receptor positive breast cancer.. 2022 , 18, e1009495	
615	High Expression of RRM1 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma.. 2022 , 15, 2607-2620	
614	Understanding Suboptimal Response to Immune Checkpoint Inhibitors.. 2022 , e2101319	1
613	Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation.. 2022 ,	0
612	Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma.. 2022 , 14,	0
611	Major Vault Protein (MVP) Associated With Mutation Is an Immune Microenvironment-Related Biomarker Promoting the Progression of Papillary Thyroid Cancer MAPK/ERK and PI3K/AKT Pathways.. 2021 , 9, 688370	1
610	Hallmarks of Resistance to Immune-Checkpoint Inhibitors.. 2022 , 10, 372-383	2
609	In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.. 2022 , 15, 29	0
608	NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation.. 2022 , 14,	1

607	Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.. 2022 , 14,	3
606	Sex Differences in Differentiated Thyroid Cancer.. 2021 ,	2
605	Application of High-Throughput Imaging Mass Cytometry Hyperion in Cancer Research.. 2022 , 13, 859414	1
604	Immune Tolerance vs. Immune Resistance: The Interaction Between Host and Pathogens in Infectious Diseases.. 2022 , 9, 827407	
603	BuFeiXiaoJiYin ameliorates the NLRP3 inflammation response and gut microbiota in mice with lung cancer companied with Qi-yin deficiency.. 2022 , 22, 121	1
602	Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer.. 2022 , 14, 1153-1164	0
601	Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity.. 2022 , 3, 100534	1
600	A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling.. 2022 , 23,	0
599	Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer.. 2022 , 12, 848783	
598	How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.. 2022 , 108962	1
597	Development and Validation of Ferroptosis- and Immune-Related lncRNAs Signatures for Breast Infiltrating Duct and Lobular Carcinoma.. 2022 , 12, 844642	1
596	Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant.. 2022 , 5, e226114	0
595	Can HALP (Hemoglobin, Albumin, Lymphocytes, and Platelets) Score Differentiate Between Malignant and Benign Causes of Acute Mechanic Intestinal Obstruction?. 2021 ,	1
594	Epithelial-mesenchymal plasticity in tumor immune evasion.. 2022 ,	2
593	ThPOK inhibits the immune escape of gastric cancer cells by inducing STPG1 to inactivate the ERK pathway.. 2022 , 23, 16	0
592	Immunosuppressive niche engineering at the onset of human colorectal cancer.. 2022 , 13, 1798	0
591	Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology.. 2022 , 14,	0
590	The current clinical landscape of personalized cancer vaccines.. 2022 , 106, 102383	1

- 589 Data-driven mathematical modeling and quantitative analysis of cell dynamics in the tumor microenvironment. **2022**, 113, 300-314
- 588 The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer.. **2022**, 41, 101725
- 587 Arginase: An emerging and promising therapeutic target for cancer treatment.. **2022**, 149, 112840 2
- 586 Tumour generated exosomal miRNAs: A major player in tumour angiogenesis.. **2022**, 166383 0
- 585 High Expression of CEMIP Correlates Poor Prognosis and the Tumor Microenvironment in Breast Cancer as a Promisingly Prognostic Biomarker.. **2021**, 12, 768140 1
- 584 Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective.. **2021**, 11, 790004 2
- 583 Challenges of cancer immunotherapy and chemotherapy during the COVID-19 pandemic.. **2021**, 3008916211068939
- 582 An Integrated Analysis of Tumor Purity of Common Central Nervous System Tumors in Children Based on Machine Learning Methods.. **2021**, 12, 707802 0
- 581 CAR-T-Zellen: Praktische Aspekte der Anwendung einer innovativen Zelltherapie. **2021**, 12, 332-341
- 580 An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas.. **2021**, 2021, 3766685 0
- 579 Immune Cell-Derived Extracellular Vesicles - New Strategies in Cancer Immunotherapy.. **2021**, 12, 771551 3
- 578 Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry.. **2021**, 10, 1
- 577 An Immune-Related Long Noncoding RNA Signature as a Prognostic Biomarker for Human Endometrial Cancer.. **2021**, 2021, 9972454 0
- 576 CD8 T Cell-Based Molecular Classification With Heterogeneous Immunogenomic Landscapes and Clinical Significance of Clear Cell Renal Cell Carcinoma.. **2021**, 12, 745945 1
- 575 Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review. **2021**, 11, e047663
- 574 Depletion of central memory CD8 T cells might impede the antitumor therapeutic effect of Mogamulizumab.. **2021**, 12, 7280 0
- 573 High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer. **2021**, 21, 1305 2
- 572 Intratumoural Effector Cell Subpopulations in Breast Cancer: a Literature Review and Own Data Report. **2021**, 11, 328-336

571	A uracil auxotroph <i>Toxoplasma gondii</i> exerting immunomodulation to inhibit breast cancer growth and metastasis.. 2021 , 14, 601	0
570	Magnetic nanoparticles in theranostics of malignant melanoma.. 2021 , 11, 127	1
569	Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.. 2021 , 13, 2076-2087	1
568	The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.. 2021 , 23, 118	1
567	The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma. 2021 , 21, 1306	0
566	Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines.. 2022 , 28, 19	5
565	Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies.. 2021 , 10,	1
564	Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.. 2021 , 12, 775761	3
563	Prognostic Value of an Immune-Related Gene Signature in Oral Squamous Cell Carcinoma.. 2021 , 11, 776979	0
562	FasL PD-L2 Identifies a Novel Immunosuppressive Neutrophil Population in Human Gastric Cancer That Promotes Disease Progression.. 2021 , e2103543	2
561	Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited irAEs.	0
560	ASYMPTOTIC ANALYSIS OF AN INTEGRO-DIFFERENTIAL SYSTEM MODELING THE BLOW UP OF CANCER CELLS UNDER THE IMMUNE RESPONSE. 2020 , 0-0	
559	Chemotherapy Effects on Immune System. 2022 , 287-302	
558	Autoimmunity regulation within the tumor microenvironment. 2022 , 51-71	
557	Systematic Elucidation and Pharmacological Targeting of Tumor-Infiltrating Regulatory T Cell Master Regulators.	1
556	Quantitative MHC class-I/-II expression levels in CDK12 mutated prostate cancer patients reveal intratumorally T cell adaptive immune response in tumors.	
555	Identification of a pyroptosis-related prognostic signature in breast cancer.. 2022 , 22, 429	0
554	DeepLION: Deep Multi-Instance Learning Improves the Prediction of Cancer-Associated T Cell Receptors for Accurate Cancer Detection. 2022 , 13,	0

553	Proteolysis-targeting chimeras (PROTACs) in cancer therapy.. 2022 , 21, 99	4
552	Tumor Microenvironment Profiling Identifies Prognostic Signatures and Suggests Immunotherapeutic Benefits in Neuroblastoma.. 2022 , 10, 814836	0
551	The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression.. 2022 , 13, 850856	1
550	Decorating Bacteria with Triple Immune Nanoactivators Generates Tumor-Resident Living Immunotherapeutics.. 2022 ,	2
549	Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancer.	0
548	Integrated immunogenomic analysis of single-cell and bulk tissue transcriptome profiling unravels a macrophage activation paradigm associated with immunologically and clinically distinct behaviors in ovarian cancer. 2022 ,	
547	Recent Therapeutic Advances in Urothelial Carcinoma: A Paradigm Shift in Disease Management.. 2022 , 103683	0
546	Integrated Analysis of Necroptosis-Related Genes for Prognosis, Immune Microenvironment Infiltration, and Drug Sensitivity in Colon Cancer.. 2022 , 9, 845271	0
545	Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes.. 2022 , 13, 2127	0
544	Pan-cancer quantification of neoantigen-mediated immunoediting in cancer evolution.	0
543	A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity.. 2022 , 13, 1925	0
542	ER β -High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer.. 2022 , 14,	0
541	Decorating Bacteria with Triple Immune Nanoactivators Generates Tumor-Resident Living Immunotherapeutics.	
540	Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.. 2022 , 13, 862527	0
539	Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review. 43,	
538	Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy.. 2022 , 13, 865964	0
537	Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.. 2022 , e29719	
536	DataSheet1.XLSX. 2018 ,	

535 DataSheet_1.pdf. **2021**,

534 DataSheet_1.pdf. **2020**,

533 Image_1.JPEG. **2019**,

532 Image_2.jpg. **2019**,

531 Image_3.JPEG. **2019**,

530 Data_Sheet_1.PDF. **2020**,

529 data_sheet_1.docx. **2018**,

528 Table_1.DOCX. **2020**,

527 Table_2.xlsx. **2020**,

526 Table_3.xlsx. **2020**,

525 Table_4.xlsx. **2020**,

524 Data_Sheet_1.docx. **2019**,

523 Table_1.docx. **2019**,

522 Data_Sheet_1.pdf. **2020**,

521 Image_1.pdf. **2020**,

520 Image_10.pdf. **2020**,

519 Image_2.pdf. **2020**,

518 Image_3.pdf. **2020**,

517 Image_4.pdf. 2020,

516 Image_5.pdf. 2020,

515 Image_6.pdf. 2020,

514 Image_7.pdf. 2020,

513 Image_8.pdf. 2020,

512 Image_9.pdf. 2020,

511 Image_1.tif. 2020,

510 Image_10.tif. 2020,

509 Image_11.tif. 2020,

508 Image_2.tif. 2020,

507 Image_3.tif. 2020,

506 Image_4.tif. 2020,

505 Image_5.tif. 2020,

504 Image_6.tif. 2020,

503 Image_7.tif. 2020,

502 Image_8.tif. 2020,

501 Image_9.tif. 2020,

500 Data_Sheet_1.PDF. 2020,

499 Image_1.TIF. **2019**,

498 Table_1.DOCX. **2019**,

497 Image_1.TIF. **2020**,

496 Table_1.DOCX. **2020**,

495 Data_Sheet_1.docx. **2020**,

494 Data_Sheet_1.zip. **2020**,

493 Image_1.tif. **2020**,

492 A variety of 'exhausted' T cells in the tumor microenvironment.. **2022**, ○

491 Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity.. **2022**, 8, eabj7002 9

490 Construction of an Immune-Autophagy Prognostic Model Based on ssGSEA Immune Scoring Algorithm Analysis and Prognostic Value Exploration of the Immune-Autophagy Gene in Endometrial Carcinoma (EC) Based on Bioinformatics.. **2022**, 2022, 7832618 ○

489 Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.. **2022**, 20, 136 1

488 Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.. **2021**, 83, 827-840 1

487 Characterization of Immune-Related Long Non-coding RNAs to Construct a Novel Signature and Predict the Prognosis and Immune Landscape of Soft Tissue Sarcoma. **2021**, 9, 709241 ○

486 Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model.. **2022**, 14, ○

485 Multimodal immune activation abilities and characteristics of reovirus.. **2021**, 13, 14176-14185

484 Comprehensive comparison of theranostic nanoparticles in breast cancer.. **2022**, 11, 1-27

483 Het immuunsysteem en samenhangende ziekten. **2022**, 185-210

482 Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice. 25, ○

- 481 Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade.. **2022**, 14, 17588359221096877 1
- 480 Evaluation of the Antitumor Immune Response Following Photofrin-Based PDT in Combination with the Epigenetic Agent 5-Aza-2'-Deoxycytidine.. **2022**, 2451, 559-567
- 479 Quantification of neoantigen-mediated immunoediting in cancer evolution.. **2022**, 0
- 478 The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value.. **2022**, 11, 0
- 477 Characterizing the Inflammatory Microenvironment in K14-HPV16 Transgenic Mice: Mast Cell Infiltration and MicroRNA Expression.. **2022**, 14,
- 476 Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development.. **2022**, 23, 190 1
- 475 Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.. **2022**, 42, 1-16 0
- 474 Resistance Mechanisms to Anti-PD Cancer Immunotherapy.. **2022**, 40, 45-74 3
- 473 Papel de la inmunoterapia en el tratamiento del cáncer endocrino. **2022**, 69, 313-315
- 472 NeoSplice: A bioinformatics method for prediction of splice variant neoantigens. 0
- 471 The implication of pyroptosis in cancer immunology: current advances and prospects. **2022**,
- 470 Development of an Antigen Delivery System for a B Cell-Targeted Vaccine as an Alternative to Dendritic Cell-Targeted Vaccines.. **2022**, 70, 341-350
- 469 USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF- κ B/PD-L1 axis to promote the development of cervical cancer.. **2022**, 110351 0
- 468 New Prognostic Gene Signature and Immune Escape Mechanisms of Bladder Cancer. **2022**, 10,
- 467 Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.. **2022**, 41, 172
- 466 CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.. **2022**, 14, 0
- 465 BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.. **2022**, 1
- 464 Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.. **2022**, 9

463	TNFRSF13B is a potential contributor to prostate cancer.. 2022 , 22, 180	
462	In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4 and CD8 T-cell epitopes for cancer immunotherapy.. 2022 ,	0
461	Lymph node colonization induces tumor-immune tolerance to promote distant metastasis.. 2022 ,	3
460	Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms.. 2022 , 1-11	1
459	Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy. 2022 , 13,	0
458	Laser ablation: Heating up the anti-tumor response in the intracranial compartment.. 2022 , 185, 114311	0
457	Considerations for personalized neoantigen vaccination in Malignant glioma.. 2022 , 186, 114312	1
456	Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ.. 2022 , 64, 35-40	1
455	Emerging Paradigm of Breast Cancer Resistance and Treatment. 2022 , 519-536	
454	Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer.. 2022 , 13, 875764	0
453	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.. 2022 , 3, 386-401	8
452	Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity. 2022 , 12,	0
451	Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. 2022 , 13,	0
450	The relationship of different preoperative inflammatory markers with the prognosis of gastric carcinoma.. 2022 ,	
449	All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity. 2022 , 13,	2
448	MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease. 2022 , 1, 1-8	0
447	Update in TIGIT Immune-Checkpoint Role in Cancer. 2022 , 12,	1
446	Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics. 2022 , 13,	0

445	A PDE Model of Breast Tumor Progression in MMTV-PyMT Mice. 2022 , 12, 807	0
444	Local anesthetics elicit immune-dependent anticancer effects.. 2022 , 10,	1
443	Cancer Immunoediting in the Era of Immuno-oncology.. 2022 ,	0
442	The role of biomarkers in personalized immunotherapy.. 2022 , 10, 32	3
441	Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. 2022 , 12,	1
440	NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59. 2022 , 12,	1
439	Small Molecule Inhibitors of Interferon-Induced JAK-STAT Signalling.	
438	An Update on the Pathology and Molecular Features of Hodgkin Lymphoma. 2022 , 14, 2647	1
437	Harnessing chitosan and poly-(L-glutamic acid)-based biomaterials towards cancer immunotherapy. 2022 , 15, 100252	0
436	Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. 2022 , 177-183	
435	A Novel Cell-Based Immunotherapy Utilizing Adoptive Transfer of Type-2 Innate Lymphoid Cells to Reduce the Growth of Tumours.	
434	Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response. 2022 , 14, 2525	0
433	Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report. 12,	0
432	Clinical impact of pretreatment albumin/globulin ratio in patients with colorectal cancer. 2022 , 101, e29190	0
431	Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy. 2022 , 13,	1
430	Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy. 2022 , 13, 314-322	0
429	Small Molecule Inhibitors of Interferon-Induced JAK-STAT Signalling.	
428	The role of immunotherapy in endocrine cancer treatment. 2022 , 69, 313-313	

- 427 Plasma profile of immune determinants predicts pathological complete response in locally advanced breast cancer patients: a pilot study. **2022**,
- 426 Hematologic malignancies and COVID-19 infection: A monocenter retrospective study. **2022**, 5,
- 425 Natural killer cells and acute myeloid leukemia: promises and challenges. 0
- 424 The immune-based prognostic score for the immunogenomic landscape analysis and application of chemotherapy in breast cancer. **2022**, 17,
- 423 Leukocyte modulation by natural products from herbal medicines and potential as cancer immunotherapy. 0
- 422 Recent Progress on Therapeutic Vaccines for Breast Cancer. 12, 2
- 421 Prognostic Significance of NLR, PLR, LMR and Tumor Infiltrating T Lymphocytes in Patients Undergoing Surgical Resection for Hilar Cholangiocarcinoma. 12, 1
- 420 Cause of Death During Renal Cell Carcinoma Survivorship: A Contemporary, Population-Based Analysis. 12,
- 419 The theory of tumor ecosystem. 0
- 418 Pleiotropic constraints promote the evolution of cooperation in cellular groups. **2022**, 20, e3001626 1
- 417 Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression. 12, 0
- 416 Elevated circASCC3 limits antitumor immunity by sponging miR-432Bp to upregulate C5a in non-small cell lung cancer. **2022**, 215774 0
- 415 Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy. **2022**, 187, 114367 0
- 414 Nanotechnology and Immunomodulators in Cancer. **2022**, 125-186 0
- 413 JAK-Inhibitoren in der pädiatrischen Rheumatologie. **2022**, 265-271
- 412 Cancer and the Immune System. **2022**, 281-316
- 411 Efficacy of oral and topical antioxidants in the prevention and management of oral mucositis in head and neck cancer patients: a systematic review and meta-analyses. 0
- 410 Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature. 13, 0

409	In situ Injection of pH- and Temperature-Sensitive Nanomaterials Increases Chemo-Photothermal Efficacy by Alleviating the Tumor Immunosuppressive Microenvironment. Volume 17, 2661-2678	1
408	Identification and Verification of Necroptosis-Related Gene Signature With Prognosis and Tumor Immune Microenvironment in Ovarian Cancer. 13,	
407	Tumor-immune metaphenotypes orchestrate an evolutionary bottleneck that promotes metabolic transformation.	0
406	Overcome tumor relapse in CAR T cell therapy.	1
405	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. 10,	4
404	Development of a novel LDHA inhibitor with potent antitumor activity and immune activation.	1
403	Circular RNAs in hepatocellular carcinoma: Recent advances. 2022 , 14, 1067-1085	
402	Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas. 2022 , 14, 3037	1
401	Personalized Neoantigen Vaccine Against Cancer. 2022 , 1, 96-100	0
400	Local Tumor Nanoparticle Thermal Therapy: A Promising Immunomodulatory Treatment For Canine Cancer.	0
399	3'UTR-HLA-G polymorphisms and circulating sHLA-G are associated with breast cancer: Evidence from a meta-analysis. 2022 , 248, 78-89	
398	The roles and therapeutic applications of cytokines in endometrial cancer. 2022 , 152, 103652	0
397	Role of Lymphocytes in Cancer Immunity and Immune Evasion Mechanisms. 2022 , 159-182	
396	The Role of the Microenvironment in Tumor Promoting Stress Responses. 2022 , 519-536	
395	Tumor-Vascular Interactions in Non-Small Cell Lung Cancer. 2022 , 497-508	
394	Drivers of EMT and Immune Evasion. 2022 , 183-194	
393	Clinical Study of Serological Detection in Patients with Gastric Cancer. 2022 , 12, 201-207	
392	Prognostic impact of an integrative analysis of [18F]FDG PET parameters and infiltrating immune cell scores in lung adenocarcinoma. 2022 , 12,	

391	Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. 2022 , 13,	1
390	Pan-cancer analysis reveals the value of FDX1 as a novel biomarker in the prognosis and immunotherapy in human tumors.	
389	Immunotherapy: an alternative promising therapeutic approach against cancers.	0
388	Emerging insights on immunotherapy in liver cancer.	0
387	Dynamic Analysis of a Model on Tumor-Immune System with Regulation of PD-1/PD-L1 and Stimulation Delay of Tumor Antigen. 2022 , 21,	0
386	Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?. 13,	0
385	Prognostic significance of the preoperative hemoglobin to albumin ratio for the short-term survival of gastric cancer patients. 2022 , 14, 580-593	0
384	High expression of RRM2 mediated by non-coding RNAs correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma. 9,	0
383	Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. 2022 , 14, 3332	0
382	IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma. OF1-OF24	2
381	mRNA vaccine development for cholangiocarcinoma: a precise pipeline. 2022 , 9,	0
380	Innate immunity as a target for novel therapeutics in triple negative breast cancer. 1-14	0
379	An M0 macrophage-related prognostic model for hepatocellular carcinoma. 2022 , 22,	0
378	Immune-based therapies in penile cancer.	1
377	A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy. 13,	0
376	Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.	1
375	Identification and Verification of Potential Biomarkers in Gastric Cancer By Integrated Bioinformatic Analysis. 13,	0
374	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. 2022 , 14, 3337	2

- 373 CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. **2022**, 14, 3361 1
- 372 Immune pressure sculps tumor cells and trims high-quality mutations. **2022**, 40, 717-719
- 371 MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. **2022**, 12, 930
- 370 Molecular and Circulating Biomarkers of Gastric Cancer. **2022**, 23, 7588 1
- 369 The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook. **2022**, 20, 834-844 1
- 368 Mixed response to cancer immunotherapy is driven by intratumor heterogeneity and differential inter-lesion immune infiltration. 0
- 367 Unraveling the Immune Microenvironment of Thymic Epithelial Tumors: Implications for Autoimmunity and Treatment. **2022**, 23, 7864 4
- 366 Immunotherapies and renal injury. **2022**, 31, 100362
- 365 World Cancer Day 2019 **Don't** Stop Thinking About Tomorrow. **2019**, 48, 42-44 2
- 364 Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic Cancer. 0
- 363 The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. 13, 0
- 362 The Multi-Omics Landscape and Clinical Relevance of the Immunological Signature of Phagocytosis Regulators: Implications for Risk Classification and Frontline Therapies in Skin Cutaneous Melanoma. **2022**, 14, 3582
- 361 Finger-powered Cell-sorting Microsystem Chip for Cancer-study Applications. **2022**, 132430 0
- 360 Characterization of KRAS Mutational Regression in Oligometastatic Patients. 13, 2
- 359 FGFR4-targeted chimeric antigen receptors (CARs) combined with anti-myeloid poly-pharmacy effectively treats orthotopic rhabdomyosarcoma. 3
- 358 The complex role of tumor-infiltrating macrophages. 5
- 357 A Novel Necroptosis-Related Prognostic Signature of Glioblastoma Based on Transcriptomics Analysis and Single Cell Sequencing Analysis. **2022**, 12, 988
- 356 Immune Checkpoint Inhibitors in Cancer Therapy **How to Overcome Drug Resistance?.** **2022**, 14, 3575 2

- 355 Splenic irradiation contributes to grade B lymphopenia after adjuvant chemoradiation for stomach cancer. **2022**, 36, 83-90 ○
- 354 Interaction between microbiota and immunity and its implication in colorectal cancer. 13, ○
- 353 Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation. 12,
- 352 An Overview on Immunogenic Cell Death in Cancer Biology and Therapy. **2022**, 14, 1564 1
- 351 Nomogram constructed by immunological and inflammatory indicators for predicting prognosis of patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy plus surgery. 12,
- 350 The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma. 13,
- 349 Ionizing radiation triggers the antitumor immunity by inducing GSDME-mediated pyroptosis in tumor cells. **2022**, ○
- 348 High preoperative white blood cell count determines poor prognosis and is associated with an immunosuppressive microenvironment in colorectal cancer. 12,
- 347 Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules. 13,
- 346 Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. **2022**, 14, 3860
- 345 The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively.
- 344 Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma. 13,
- 343 Immune Biomarkers in Blood from Sarcoma Patients: A Pilot Study. **2022**, 29, 5585-5603
- 342 JAK Inhibitors in Rheumatoid Arthritis.
- 341 CDK5RAP3 acts as a tumour suppressor in gastric cancer through the infiltration and polarization of tumour-associated macrophages.
- 340 Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity. **2022**, 7, ○
- 339 Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients. **2022**, ○
- 338 Pericyte mediates the infiltration, migration, and polarization of macrophages by CD163/MCAM axis in glioblastoma. **2022**, 104918 ○

- 337 Simultaneous Photoactivation of cGAS-STING Pathway and Pyroptosis by Pt(II)-Triphenylamine Complexes for Cancer Immunotherapy. 2
- 336 CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment. 13, 0
- 335 A Novel Ferroptosis-Related Gene Signature for Prognosis Prediction in Ewing Sarcoma. **2022**, 2022, 1-22
- 334 Interleukin-17D promotes lung cancer progression by inducing tumor-associated macrophage infiltration via the p38 MAPK signaling pathway. **2022**, 14, 6149-6168
- 333 Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. 12, 0
- 332 CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma. 13, 0
- 331 Integration of miRNA:mRNA Co-Expression Revealed Crucial Mechanisms Modulated in Immunogenic Cancer Cell Death. **2022**, 10, 1896
- 330 Construction of a novel signature and prediction of the immune landscape in gastric cancer based on necroptosis-related genes. **2022**, 12,
- 329 STK11 mutation affects the killing effect of NK cells to promote the progression of lung adenocarcinoma.
- 328 Colorectal cancer vaccines: The current scenario and future prospects. 13, 0
- 327 A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of TOP1MT. 13,
- 326 Simultaneous Photoactivation of cGAS-STING Pathway and Pyroptosis by Pt(II)-Triphenylamine Complexes for Cancer Immunotherapy.
- 325 Nanomaterials: A powerful tool for tumor immunotherapy. 13, 1
- 324 Bioinformatic analysis of RNA-seq data from TCGA database reveals prognostic significance of immune-related genes in colon cancer. **2022**, 101, e29962
- 323 SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma. 13,
- 322 The immune-related role of beta-2-microglobulin in melanoma. 12, 0
- 321 Immune-modified Glasgow prognostic score: A new prognostic marker for head and neck cancer. 0
- 320 A novel signature to predict thyroid cancer prognosis and immune landscape using immune-related LncRNA pairs. **2022**, 15, 1

- 319 Immune cellular components and signaling pathways in the tumor microenvironment. **2022**, 1
- 318 A comprehensive analysis of gasdermin family gene as therapeutic targets in pan-cancer. **2022**, 12,
- 317 Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma. **2022**, 22,
- 316 Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. **2022**, 349, 844-875 2
- 315 Advanced nanovaccines based on engineering nanomaterials for accurately enhanced cancer immunotherapy. **2022**, 472, 214788 0
- 314 Immune-regulating camouflaged nanoplatforms: A promising strategy to improve cancer nano-immunotherapy. **2023**, 21, 1-19 0
- 313 Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature. Volume 17, 4293-4306 0
- 312 Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. 13, 0
- 311 Dexamethasone and compliance affect TTFields efficacy to glioblastoma patients: a systematic review and meta-analysis. **2022**, 8, 0
- 310 Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. 11, 0
- 309 Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. 13, 1
- 308 Tannins in Terminalia bellirica inhibits hepatocellular carcinoma growth via re-educating tumor-associated macrophages and restoring CD8+T cell function. **2022**, 154, 113543 0
- 307 Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?. **2022**, 110, 102462 1
- 306 The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022. **2022**, 243, 114680 0
- 305 A double-edged sword: The HBV-induced non-coding RNAs alterations in hepatocellular carcinoma. **2023**, 47, 27-32 0
- 304 Background: Immunology and Cancer. **2022**, 1-4 0
- 303 NKG2D-ligands in liquid biopsy. The importance of soluble and vesicle-bound proteins for immune modulation. **2022**, 0
- 302 Immunobiology of Testicular Cancer. **2022**, 0

301	Preclinical Animal Models of Cancer: Applications and Limitations. 2022 , 1-21	0
300	Tumor-infiltrating Lymphocytes as Markers of the Antitumor Therapy Efficacy: Myth or Reality?. 2022 ,	0
299	Role of Tumor-associated neutrophils in the breast tumor microenvironment. 2022 , 171-194	0
298	Horizontal Integration: Disease [Cancer Systems Biology. 2022 ,	0
297	A novel necroptosis-related gene signature for predict prognosis of glioma based on single-cell and bulk RNA sequencing. 9,	0
296	Comparative analysis of some immunological parameters depending on the tumor location on the right and left sides of colon. 2022 , 20-28	0
295	Risk of Severe COVID-19 Outcomes Among Patients with Immune-Mediated Inflammatory Diseases or Malignancies: A Retrospective Analysis of Real-World Data in the United States.	0
294	Micro-RNA193a-3p Inhibits Breast Cancer Cell Driven Growth of Vascular Endothelial Cells by Altering Secretome and Inhibiting Mitogenesis: Transcriptomic and Functional Evidence. 2022 , 11, 2967	1
293	Large-scale bulk RNA-seq analysis defines immune evasion mechanism related to mast cell in gliomas. 13,	0
292	Immune checkpoint inhibitor-induced myocarditis. 2022 , 2, 35-43	0
291	Quantitative evaluation by SPECT/CT of Radionuclide Therapy with Radium-223 Chloride of Bone Metastases in Metastatic Castration-resistant Prostate Cancer. 2022 , 5, 29-42	0
290	Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant ChemotherapyResistant Early Breast Cancers. OF1-OF15	0
289	GSTA4 governs melanoma immune resistance and metastasis.	0
288	Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. 2022 , 21,	0
287	New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?. 2022 , 10, 1607	2
286	KLHDC8A Expression in Association with Macrophage Infiltration and Oxidative Stress Predicts Unfavorable Prognosis for Glioma. 2022 , 2022, 1-14	1
285	The Prediction of Necroptosis-Related lncRNAs in Prognosis and Anticancer Therapy of Colorectal Cancer. 2022 , 2022, 1-21	0
284	Cuproptosis patterns and tumor immune infiltration characterization in colorectal cancer. 13,	0

283	Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1/DPP4 axis in hepatocellular carcinoma. 2022 , 41,	0
282	Mechanism underlying circRNA dysregulation in the TME of digestive system cancer. 13,	0
281	Immune checkpoint blockade enhances chemophotherapy in a syngeneic pancreatic tumor model. 2022 , 6, 036105	0
280	Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells.	0
279	Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment.	2
278	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. 13,	0
277	Genetic influences in cancer-associated myositis.	0
276	Prognostic significance of Naples prognostic score in operable renal cell carcinoma. 9,	0
275	Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach. 2022 , 10, 1493	0
274	MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?. 2022 , 14, 4294	0
273	Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis. 13,	1
272	Basics of immunooncology and immunotherapy in oncology. 2022 , 129-139	0
271	Personalized Cancer Vaccines Targeting Neoantigens. 2022 , 1-21	0
270	A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. 2022 , 29, 107327482211305	0
269	Charakterisierung des Tumormikromilieus mittels Hochmultiplexmikroskopieverfahren.	0
268	Exploring the role of neutrophil-to-lymphocyte ratio and blood chemistry in head and neck adenoid cystic carcinomas treated with carbon ion radiotherapy. 2022 ,	0
267	How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy. 2022 , 10, 2498	1
266	Chromosomal Instability, Selection and Competition: Factors That Shape the Level of Karyotype Intra-Tumor Heterogeneity. 2022 , 14, 4986	1

- 265 Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. **2022**, 10, 2628 ○
- 264 Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer. ○
- 263 Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis. 9, ○
- 262 Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response. ○
- 261 COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. **2022**, 110495 1
- 260 Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. **2022**, 23, 13241 ○
- 259 TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems. **2022**, 14, 5125 2
- 258 Analysis of pre-diagnostic values of leukocytes count and neutrophil-to-lymphocyte ratio in patients who develop colorectal cancer. ○
- 257 Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. **2022**, 10, 2511 ○
- 256 Effects of Low-dose Splenic Irradiation on T lymphocyte Immune Function. **2022**, 123, 486-491 ○
- 255 Mechanisms of Cancer Metastasis. **2022**, 2
- 254 Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment. **2022**, 8, e11081 1
- 253 A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer. 13, ○
- 252 Synergy of Polydopamine Nanovaccine and Endostar Alginate Hydrogel for Improving Antitumor Immune Responses Against Colon Tumor. Volume 17, 4791-4805 ○
- 251 Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy. 13, ○
- 250 Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. **2022**, 479, 2219-2260 2
- 249 Tumor immune checkpoints and their associated inhibitors. **2022**, 23, 823-843 ○
- 248 Systemic immune-inflammation index and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta-analysis. ○

- 247 LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. **2022**, 27, 0
- 246 Transcription factor CASZ1 increases an oncogenic transcriptional process in tumorigenesis and progression of glioma cells. **2022**, 3, 0
- 245 Mining the Immunopeptidome for Antigenic Peptides in Cancer. **2022**, 14, 4968 0
- 244 Morbidity and mortality among patients with breast cancer receiving anticancer treatment before and during the COVID-19 pandemic: A single tertiary center experience. **2022**, 24, 0
- 243 Tumor micronecrosis predicts poor prognosis of patients with hepatocellular carcinoma after liver transplantation. 0
- 242 Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF- κ B pathway. **2022**, 122361 0
- 241 A double-edged sword in tumor angiogenesis and progression. Dual roles of mast cells, macrophages, and neutrophils. **2022**, 240, 154167 1
- 240 TREM2 knockdown improves the therapeutic effect of PD-1 blockade in hepatocellular carcinoma. **2022**, 636, 140-146 1
- 239 The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. **2022**, 310, 121138 0
- 238 Immunotherapy in gynecologic malignancies. **2023**, 506-520.e7 0
- 237 Molecular hallmarks of cancer. **2023**, 489-505.e5 0
- 236 The thin red line between the immune system and cancer evolution. **2023**, 27, 101555 1
- 235 RAS: Circuitry and therapeutic targeting. **2023**, 101, 110505 0
- 234 Type I and II interferon signaling in colorectal cancer liver metastasis. **2023**, 161, 156075 1
- 233 Potential roles of hyaluronic acid in in vivo CAR T cell reprogramming for cancer immunotherapy. 0
- 232 Newest Approaches in Immunotherapy for Non-Hodgkin's Lymphoma. 40-48 0
- 231 The mechanisms on evasion of anti-tumor immune responses in gastric cancer. 12, 0
- 230 Human neutrophils vs murine neutrophils: Does it matter?. 1

- 229 Molecular subtyping of esophageal squamous cell carcinoma by large-scale transcriptional profiling: Characterization, therapeutic targets, and prognostic value. 13, 0
- 228 Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer. Volume 17, 5209-5227 0
- 227 Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. **2022**, 13, 0
- 226 Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer. **2022**, 23, 13723 0
- 225 The influence of stimulated thyroglobulin and lymphocyte subsets before radioiodine therapy on the therapeutic response in patients with intermediate- and high-risk papillary thyroid carcinoma. 0
- 224 Long-term (>5-year) survivors among unresectable or metastatic cancer patients treated with zoledronate-activated killer cells: Seven case reports. **2022**, 10, 0
- 223 The molecular basis of immuno-radiotherapy. 1-22 0
- 222 DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. **2022**, 13, 0
- 221 N-glycosylation regulates intrinsic IFN- γ resistance in colorectal cancer: implications for immunotherapy.. **2022**, 0
- 220 Autophagy in Cancer Metastasis. **2023**, 259-285 0
- 219 Extracellular Vesicles in Multiple Myeloma—Tracking the Code to a Better Understanding of the Disease. **2022**, 14, 5575 0
- 218 A novel prognostic model for prostate cancer based on androgen biosynthetic and catabolic pathways. 12, 0
- 217 Molecular Events in the Melanogenesis Cascade as Novel Melanoma-Targeted Small Molecules: Principle and Development. **2022**, 14, 5588 2
- 216 Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. **2022**, 1
- 215 Prognostic and Clinical Value of the Systemic Immune-Inflammation Index in Biliary Tract Cancer: A Meta-Analysis. **2022**, 2022, 1-11 0
- 214 Resemblance of the Recurrence Patterns in Primary Systemic, Primary Surgery and Secondary Oncoplastic Surgery. **2022**, 29, 8874-8885 0
- 213 Immune System-Related Biomarkers as a Tool for Diagnosis in Oral Cancer. **2022**, 1-21 0
- 212 Immunotherapy and Targeted Therapy in the Management of Oral Cancers. **2022**, 0

211	Oligometastatic Disease: Basic Aspects and Clinical Results in NSCLC. 2022,	0
210	Inflammasomes and cancer. 2023, 441-463	0
209	A nanoformulation for immunosuppression reversal and broad-spectrum self-amplifying antitumor ferroptosis-immunotherapy. 2023, 292, 121936	0
208	The Tumor Microenvironment in Hepatocellular Carcinoma. 2022,	0
207	Chapter 13. The Intersection of Biomaterials, Tissue Engineering, and Immuno-oncology. 2022, 342-383	0
206	The Anticancer Power of the Immune System [New Perspectives for Patients with Triple-Negative Breast Cancer. 54-62	0
205	Research status and prospect of immune checkpoint inhibitors for melanoma. 2022,	0
204	Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy. 2022, 14, 2606	0
203	Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.	0
202	Advances in the Lung Cancer Immunotherapy Approaches. 2022, 10, 1963	0
201	Metabolism in Cancer Stem Cells: Targets for Clinical Treatment. 2022, 11, 3790	1
200	Myeloid cell reprogramming alleviates immunosuppression and promotes clearance of metastatic lesions. 12,	0
199	Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. 2022, 35-40	0
198	Construction and Validation of a novel signature for Immune response prediction in clear cell Renal Cell Carcinoma.	0
197	Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer. 12,	0
196	The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. 2022, 31, 1203-1226	0
195	Study of epirubicin sustained release chemoablation in tumor suppression and tumor microenvironment remodeling. 13,	1
194	Exposure of Immunogenic Tumor Antigens in Surrendered Immunity and the Significance of Autologous Tumor Cell-Based Vaccination in Precision Medicine. 2023, 24, 147	0

193	The Infiltration of Neutrophil Granulocytes Due to Loss of PTEN Was Associated with Poor Response to Immunotherapy in Renal Cell Carcinoma. Volume 15, 6553-6567	0
192	Interferon-gamma signaling promotes melanoma progression and metastasis.	0
191	Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy.	0
190	Cancer Immunotherapy Beyond Checkpoint Blockade. 2022 , 4, 563-578	0
189	Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy. 2023 , 15, 109	0
188	Significance of regulatory T cells in cancer immunology and immunotherapy.	0
187	Cancer immunotherapeutic effect of carboxymethylated β -D-glucan coupled with iron oxide nanoparticles via reprogramming tumor-associated macrophages. 2022 ,	1
186	Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells. 2022 , 10, e005200	0
185	Regulatory T cells infiltrate the tumor-induced tertiary lymphoid structures and are associated with poor clinical outcome in NSCLC. 2022 , 5,	1
184	Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics. 2023 , 15, 82	1
183	A Cancer-Associated Fibroblast Classification Framework for Single-Cell Data.	0
182	Role of T cells in cancer immunotherapy: Opportunities and challenges. 2022 ,	1
181	Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. 2022 , 14, 6034	1
180	Influence of Perioperative Anesthesia on Cancer Recurrence: from Basic Science to Clinical Practice.	0
179	The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. 2022 , 14, 6151	0
178	Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes. 2022 , 56, 409-419	0
177	Novel Roles of Nanog in Cancer Cells and Their Extracellular Vesicles. 2022 , 11, 3881	0
176	Age-associated remodeling of T cell immunity and metabolism. 2022 ,	0

- 175 Weighted gene co-expression network reveals driver genes contributing to phenotypes of anaplastic thyroid carcinoma and immune checkpoint identification for therapeutic targets. 12,
- 174 The function of natural compounds in important anticancer mechanisms. 12,
- 173 Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. **2023**, 216062
- 172 Advances of mRNA vaccine in tumor: a maze of opportunities and challenges. **2023**, 11,
- 171 Potential Targets and Mechanisms of *Dalbergia odorifera* on Treating Lung Adenocarcinoma Explored by Network Pharmacology. **2023**, 19, 52-63
- 170 Immunoediting instructs tumor metabolic reprogramming to support immune evasion. **2023**, 35, 118-133.e7
- 169 Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?. **2023**, 15, 175883592211480
- 168 Exploring the landscape of immunotherapy approaches in sarcomas. 12,
- 167 Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy. **2023**, 11, 169
- 166 Natural biomolecules and derivatives as anticancer immunomodulatory agents. 13,
- 165 Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. **2023**, 15, 543
- 164 Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. **2023**, 15, 321
- 163 Time to Sleep: Immunologic Niche Switches Tumor Dormancy at Metastatic Sites. **2023**, 1-27
- 162 Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer. 13,
- 161 Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study. **2023**, 30, 1032-1045
- 160 Significance of tumor-associated neutrophils, lymphocytes, and neutrophil-to-lymphocyte ratio in non-invasive and invasive bladder urothelial carcinoma.
- 159 Extracellular Vesicles Are Important Mediators That Regulate Tumor Lymph Node Metastasis via the Immune System. **2023**, 24, 1362
- 158 Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell Renal Cell Carcinoma.

- 157 Development and validation of a GRGPI model for predicting the prognostic and treatment outcomes in head and neck squamous cell carcinoma. 12, ○
- 156 Depression and Cancer: The Inflammatory Bridge. **2023**, ○
- 155 Neoantigens: promising targets for cancer therapy. **2023**, 8, 3
- 154 Knowing the myeloid-derived suppressor cells : Another enemy of sarcomas patients. **2023**, ○
- 153 Exosomal miR-211-5p regulates glucose metabolism, pyroptosis, and immune microenvironment of melanoma through GNA15. **2023**, 106660 ○
- 152 High tissue expression of TLRs combined with high density of tumor infiltrating lymphocytes predicts a better prognosis in colorectal cancer patients. **2023**, 18, e0280085 ○
- 151 Gradient differences of immunotherapy efficacy in metastatic melanoma related to sunlight exposure pattern: A population-based study. 12, ○
- 150 Histaminergic System as a Promising Target for Breast Cancer Treatment. **2023**, ○
- 149 Molecular Modeling Insights into the Structure and Behavior of Integrins: A review. **2023**, 12, 324 ○
- 148 Development and validation of a novel nomogram for predicting overall survival in gastric cancer based on inflammatory markers. 15, 49-59 ○
- 147 Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling the responses of T-cells, myeloid derived suppressor cells and NK cells. ○
- 146 MHC II immunogenicity shapes the neoepitope landscape in human tumors. ○
- 145 Early immune pressure makes tumors metabolically stronger. **2023**, 35, 3-5 ○
- 144 Antitumor effect of invasive *Lactobacillus plantarum* delivering associated antigen gene sHSP between *Trichinella spiralis* and Lewis lung cancer cells. **2023**, 115, 109708 ○
- 143 SAMD13 as a Novel Prognostic Biomarker and its Correlation with Infiltrating Immune Cells in Hepatocellular Carcinoma. **2022**, 28, 260-275 ○
- 142 Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression. **2023**, 11, 99 ○
- 141 RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer. **2022**, 41, ○
- 140 Construction of an Immune Escape-Related Signature in Clear Cell Renal Cell Carcinoma and Identification of the Relationship between IFNAR1 and Immune Infiltration by Multiple Immunohistochemistry. **2023**, 15, 169 ○

139	Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. 2023 , 15, 257	1
138	Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. 2023 , 24, 599	0
137	Tumor-infiltrating lymphocytes: Prognostic considerations and current trials as adoptive cell therapy. 2023 , 403-426	0
136	HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events.	0
135	Tumor micronecrosis predicts poor prognosis of patients with hepatocellular carcinoma after liver transplantation. 2023 , 23,	0
134	Clear Cell Renal Cell Carcinoma: From Biology to Treatment. 2023 , 15, 665	2
133	Transcriptomic and Functional Evidence That miRNA193a-3p Inhibits Lymphatic Endothelial Cell (LEC) and LEC + MCF-7 Spheroid Growth Directly and by Altering MCF-7 Secretome. 2023 , 12, 389	0
132	Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. 2023 , 121459	0
131	Oncolytic virus cancer therapeutic options and integration of artificial intelligence into virus cancer research. 2023 , 61-80	0
130	HLA-G: A Novel Immune Checkpoint for Solid Cancer Immunotherapy. 2023 , 1-27	0
129	Identification of Potential Hub Genes Related to Aflatoxin B1, Liver Fibrosis and Hepatocellular Carcinoma via Integrated Bioinformatics Analysis. 2023 , 12, 205	0
128	Preclinical Animal Models of Cancer: Applications and Limitations. 2023 , 1051-1071	0
127	Identification of prognostic immune-related lncRNA signature predicting the overall survival for colorectal cancer. 2023 , 13,	0
126	Do macrophages follow the beat of circadian rhythm in TIME (Tumor Immune Microenvironment)?. 2023 , 12, 101	0
125	Aberrant N-glycosylation in cancer: MGAT5 and β 1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression.	0
124	MicroRNAs affecting the susceptibility of melanoma cells to CD8 + T cell-mediated cytotoxicity. 2023 , 13,	0
123	Immunotherapies in rare cancers. 2023 , 22,	0
122	Novel insights into the impact of liver inflammatory responses on primary liver cancer development. 2023 ,	0

- 121 Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens. ○
- 120 Cancer Metastasis: Dynamic Hetero-cellular Communications Between Cancer Cells and Host Tissues. **2023**, 1-31 ○
- 119 Current Treatment Approaches to Breast Cancer. **2023**, 23-51 ○
- 118 Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial. ○
- 117 Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients. 14, ○
- 116 Research into the characteristic molecules significantly affecting liver cancer immunotherapy. 14, ○
- 115 Nanoscale imaging of CD47 informs how plasma membrane modifications shape apoptotic cell recognition. **2023**, 6, ○
- 114 Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients. 14, ○
- 113 Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment. **2023**, 13, ○
- 112 Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. **2023**, 161, 1-36 ○
- 111 Prognostic value of tumor-associated regulatory T-cells as a biomarker in non-small cell lung cancer: a systematic review and meta-analysis. ○
- 110 Advances in the application of immune checkpoint inhibitors in gynecological tumors. **2023**, 117, 109774 ○
- 109 Oncogenic drivers dictate immune control of acute myeloid leukemia. **2023**, 14, ○
- 108 Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells. **2023**, 122126 ○
- 107 Cancer stem cell in prostate cancer progression, metastasis and therapy resistance. **2023**, 1878, 188887 ○
- 106 TREM2: A new player in the tumor microenvironment. **2023**, 67, 101739 ○
- 105 Microbial metabolites and immunotherapy: Basic rationale and clinical indications. **2023**, 67, 101755 ○
- 104 Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo. **2023**, 61, 102650 ○

103	Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study. 2023 , 90, 105555	0
102	Immunology and immunotherapy of cholangiocarcinoma.	1
101	Production of Monoclonal antibodies to membrane components of human colorectal cancer HCT-116 cell line for diagnostic purposes. 2023 , 16, 104627	0
100	An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. 2023 , 88, 104452	0
99	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. 2023 , 12, 218	0
98	SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma. 2023 , 15, 906	0
97	Epigenetic modification of CSDE1 locus dictates immune recognition of nascent tumorigenic cells. 2023 , 15,	0
96	Radiotherapy/Chemotherapy-Immunotherapy for Cancer Management: From Mechanisms to Clinical Implications. 2023 , 2023, 1-9	0
95	Characterization of the microenvironment in different immune-metabolism subtypes of cervical cancer with prognostic significance. 14,	0
94	Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. 2023 , 7,	0
93	Interplay between tumor-derived factors and tumor-associated neutrophils: opportunities for therapeutic interventions in cancer.	0
92	Extracellular Vesicles in Lung Cancer: Bystanders or Main Characters?. 2023 , 12, 246	1
91	The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: A review. 14,	0
90	Regulation of immunological tolerance by the p53-inhibitor iASPP. 2023 , 14,	0
89	Prognostic value of diffuse reduction of spleen density on postoperative survival of pancreatic ductal adenocarcinoma: A retrospective study.	0
88	Regulation of innate immune system function by the microbiome: Consequences for tumor immunity and cancer immunotherapy. 2023 , 66, 101724	0
87	How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.	0
86	Shining the light on mesenchymal stem cell-derived exosomes in breast cancer. 2023 , 14,	0

- 85 Biodegradable photothermal thermosensitive hydrogels treat osteosarcoma by reprogramming macrophages. **2023**, 11, 2818-2827 ○
- 84 STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma. 14, ○
- 83 Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. 14, ○
- 82 GPR65 as a potential immune checkpoint regulates the immune microenvironment according to pan-cancer analysis. **2023**, 9, e13617 ○
- 81 Oncogenic drivers dictate immune control of acute myeloid leukemia. ○
- 80 Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. **2023**, 23, ○
- 79 Research progress on the immunomodulatory mechanism of acupuncture in tumor immune microenvironment. 14, ○
- 78 Development of a nomogram to predict the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis on antivirals. 13, ○
- 77 PTPN18 Serves as a Potential Oncogene for Glioblastoma by Enhancing Immune Suppression. **2023**, 2023, 1-21 ○
- 76 LncRNA and its role in gastric cancer immunotherapy. 11, ○
- 75 Precision Delivery of Dual Immune Inhibitors Loaded Nanomodulator to Reverse Immune Suppression for Combinational Photothermal-Immunotherapy. 2206441 ○
- 74 Immune surveillance of brain metastatic cancer cells is mediated by IFITM1. **2023**, 42, ○
- 73 Dynamic network biomarker to determine the critical point of breast cancer stage progression. **2023**, 30, 453-465 ○
- 72 Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. 13, ○
- 71 Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors. ○
- 70 Dishevelled 2 regulates cancer cell proliferation and T cell mediated immunity in HER2-positive breast cancer. **2023**, 23, ○
- 69 The Role of Inflammatory Cell Infiltration in Urogenital Cancers. **2023**, ○
- 68 Unobvious Neutrophil Extracellular Traps Signification in the Course of Oral Squamous Cell Carcinoma: Current Understanding and Future Perspectives. **2023**, 30, 107327482311593 ○

- 67 Prognostic Value and Immune Infiltration of HPV-Related Genes in the Immune Microenvironment of Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma. **2023**, 15, 1419 ○
- 66 Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. **2023**, 11, e006234 ○
- 65 Roles of E2F family members in the diagnosis and prognosis of head and neck squamous cell carcinoma. **2023**, 16, ○
- 64 Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer. **2023**, 15, 1532 ○
- 63 Chemerin and Chemokine-like Receptor 1 Expression in Ovarian Cancer Associates with Proteins Involved in Estrogen Signaling. **2023**, 13, 944 ○
- 62 Early inflammatory biomarkers and melanoma survival. ○
- 61 Tumor Evasion of the Immune System: Role of Interferon and Tumor Necrosis Factor in Cancer. **2022**, 1-27 ○
- 60 Immune Gene Therapy of Cancer. **2023**, 1-45 ○
- 59 Interaction of gut microbiota with the tumor microenvironment: A new strategy for antitumor treatment and traditional Chinese medicine in colorectal cancer. 10, ○
- 58 The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. **2023**, 13, ○
- 57 Major and minor populations of lymphocytes: local features in different stages of colon cancer. **2023**, 4, 34-42 ○
- 56 Diversity of immune checkpoints in cancer immunotherapy. 14, ○
- 55 Prognostic role of the pretreatment systemic immune-inflammation index in patients with glioma: A meta-analysis. 14, ○
- 54 Acute myocarditis with transient myocardial thickening in two oncologic patients treated with anti-GD2 immunotherapy. ○
- 53 Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance. **2023**, 31, 418-432.e8 ○
- 52 Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. **2023**, 28, 17-26 ○
- 51 PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors Response and Survival in Advanced Melanoma Patients in Brazil. **2023**, 13, 1041 ○
- 50 Major and minor populations of lymphocytes: local features in different stages of colon cancer. **2023**, 4, 34-42 ○

- 49 Chronic hypoxia is associated with transcriptomic reprogramming and increased genomic instability in cancer cells. 11, ○
- 48 The Role of PRMT5 in Immuno-Oncology. **2023**, 14, 678 ○
- 47 Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. **2023**, 15, 1680 ○
- 46 The Undesirable and Desirable Functions of DAMPs in Allograft and Tumor Rejection. **2023**, 659-673 ○
- 45 Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients. ○
- 44 EBV -positive pyothorax-associated lymphoma expresses CXCL9 and CXCL10 chemokines that attract cytotoxic lymphocytes via CXCR3. ○
- 43 Analysis of the Clinicopathological Characteristics, Prognosis, and Lymphocyte Infiltration of Esophageal Neuroendocrine Neoplasms: A Surgery-Based Cohort and Propensity-Score Matching Study. **2023**, 15, 1732 ○
- 42 Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer. **2023**, 23, ○
- 41 Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes. 14, ○
- 40 Persistence is key: Refining immunotherapy response prediction. **2023**, 56, 472-474 ○
- 39 Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective studies. **2023**, 118, 110019 ○
- 38 Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. **2023**, 42, ○
- 37 A phase-field model for non-small cell lung cancer under the effects of immunotherapy. ○
- 36 Cancer Immunotherapy: A Brief History, The Latest Development of Typical Subtypes and Therapy Combination. 30, 34-43 ○
- 35 Epigenetic state determines the in vivo efficacy of STING agonist therapy. **2023**, 14, ○
- 34 Six immune-related promising biomarkers may promote hepatocellular carcinoma prognosis: a bioinformatics analysis and experimental validation. **2023**, 23, ○
- 33 TLImmuno2: predicting MHC class II antigen immunogenicity through transfer learning. ○
- 32 Modeling the role of immune cell conversion in the tumor-immune microenvironment. ○

- 31 Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. **2023**, 22, ○
- 30 Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases. ○
- 29 Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple-Negative Breast Cancer Treatment. ○
- 28 Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial. **2023**, 15, 2030 ○
- 27 Targeting the Molecular and Immunologic Features of Leiomyosarcoma. **2023**, 15, 2099 ○
- 26 Increased SEC23A Expression Correlates with Poor Prognosis and Immune Infiltration in Stomach Adenocarcinoma. **2023**, 15, 2065 ○
- 25 Crosstalk between triple negative breast cancer and microenvironment. **2023**, 14, 284-293 ○
- 24 Smad3 is essential for polarization of tumor-associated neutrophils in non-small cell lung carcinoma. **2023**, 14, ○
- 23 Comparative oncology: overcoming human cancer through companion animal studies. ○
- 22 Immune cell death-related lncRNA signature as a predictive factor of clinical outcomes and immune checkpoints in gastric cancer. 14, ○
- 21 C4orf47 is a Novel Prognostic Biomarker and Correlates with Infiltrating Immune Cells in Hepatocellular Carcinoma. **2023**, 29, 11-25 ○
- 20 Increased tumor-associated mast cells facilitate thyroid cancer progression by inhibiting CD8+ T cell function through galectin-9. 56, ○
- 19 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 18 The novel putative methyltransferase METTL7A as one prognostic biomarker potentially associated with immune infiltration in human renal cancer. **2023**, 9, e15371 ○
- 17 The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer. ○
- 16 Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer. 14, ○
- 15 Immune plasticity in pregnancy-associated breast cancer tumorigenesis. Publish Ahead of Print, ○
- 14 Signature identification based on immunogenic cell death-related lncRNAs to predict the prognosis and immune activity of patients with endometrial carcinoma. ○

- 13 Impact of risk factors on early cancer evolution. **2023**, 186, 1541-1563 ○
- 12 Extracellular Vesicles in Breast Cancer: From Biology and Function to Clinical Diagnosis and Therapeutic Management. **2023**, 24, 7208 ○
- 11 Calcifications in triple-negative breast cancer: Molecular features and treatment strategies. **2023**, 9, ○
- 10 Ovarian cancer-associated immune exhaustion involves SPP1+ T cell and NKT cell, symbolizing more malignant progression. 14, ○
- 9 Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity. ○
- 8 Role and research progress of hematological markers in laryngeal squamous cell carcinoma. **2023**, 18, ○
- 7 Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. **2023**, 154470 ○
- 6 Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression. **2023**, ○
- 5 Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. **2023**, ○
- 4 Ubiquitin-conjugating enzyme E2T predicts the tumour microenvironment immune characteristics and prognosis of hepatocellular carcinoma: Bioinformatics-based approach. ○
- 3 The Prognostic Role of the Immune Microenvironment in Sinonasal Intestinal-Type Adenocarcinoma: A Computer-Assisted Image Analysis of CD3+ and CD8+ Tumor-Infiltrating Lymphocytes. **2023**, 13, 726 ○
- 2 Microendoscopy in vivo for the pathological diagnosis of cervical precancerous lesions and early cervical cancer. **2023**, 18, ○
- 1 Perivascular localized cells commit erythropoiesis in PDGF-B-expressing solid tumors. ○